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ABSTRACT
The Prediction of Hormone-Dependence in Mammary Cancer.
A review has been made of the literature concerning clinical
response rates to endocrine therapies for advanced mammary cancer
and the need for a predictor of response has been identified.
Various postulated predictors of response have been critically
reviewed and Oestrogen Receptor (E/R) status has been identified
as the best, currently available, approach. The main limitations
of E/R status are, firstly, the poor predictive value of a
positive result and, secondly, the complex nature of current
techniques for its determination.
Two approaches to the prediction of hormone-dependence, aimed
at overcoming these limitations of E/R status, have been invest¬
igated. Biochemical and histochemical systems for the identif¬
ication of tissue peroxidase, a postulated, alternative marker
for oestrogen-dependence, have been established. Peroxidase
levels have been measured in a range of normal rat tissues, in
rat mammary tumour models of hormone-dependent and -independent
growth and in human mammary tumours and have been compared with
levels of E/R and also of Progestogen Receptor (Pg/R). A
relationship between peroxidase activity and hormone-dependence
has been confirmed but the predictive value of peroxidase
determination appears to be inferior to that of E/R assay.
The feasibility of a histochemical approach to the identification
of E/R has been investigated. The effects of histochemical
processing, including methods of tissue fixation, on E/R activity
have been studied using tritiated oestradiol as tracer. Conjugates
of oestradiol with tracers which can be visualised under the
light,or fluorescence, microscope have been synthesised and
evaluated. It has been demonstrated that histochemical processing
results in considerable losses of detectable E/R activity and £hat
oestradiol labelled with histochemical tracers has a very small
ability to bind to E/R. Nevertheless, uptake of labelled oestradiol
by oestrogen-target tissues, including some human mammary cancers,
has been demonstrated and such uptake may be related to bona fide
E/R activity.
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PART I
INTRODUCTORY REVIEW
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I. THE CONCEPT Off HORHONE-D3PBNDSN05 IN MAI-MART CANCER
The origin of the concept that malignant cells are
not always autonomous "but may retain sensitivity to the
same hormonal influences that govern the behaviour of the
parent tissue is credited to Charles Huggins and
Peyton Rous. In 1966 they were jointly awarded the Nobel
Prize in medicine and physiology in recognition of the
far-reaching implications of the concept they had evolved.
Endocrine ablation had been successfully undertaken for the
control of advanced malignancy since the late 19th century
but its basis had been purely empirical, and it was the
classic experimental work of Huggins which led to an
understanding of the nature of the relationship between
the gonads and certain cancers. In 1940, Huggins and Clark
described studies into the effects of castration and of the
administration of hormones on hyperplastic prostate in the
experimental dog. Their observations led them to investigate
the effects of orchidectomy on prostatic cancer in man.
They found a rewarding rate of response (Huggins et al., 1941).
In a lucid and enthusiastic review of "Advances in
Cancer Research", Rous (1947) revealed his insight into the
far-reaching implications of Huggins' laboratory and
clinical observations:
i
"The significance of this discovery far transcends
its practical application; for it means that thought
and endeavour in cancer research have been mis¬
directed in consequence of the belief that tumour
cells are anarchic No one had realised that
neoplastic cells, making such attempts at differ¬
entiation, might also respond, in line of duty, to
normal, physiological influences such as the
hormones exert."
This concept of hormone dependence was soon applied
to the behaviour of mammary, as well as prostatic cancer.
Tears of empiricism had suggested, and, more recently,
laboratory studies in cell and tissue culture (Borthwick
and Smellie, 1975; Montessori et al., 1977; Lippman and
Bolan, 1975; Welsch and Rivera, 1972; Scott et al., 1979)
have confirmed, that a proportion of human and experimental
cancers exhibit grovrth-dependence on oestrogen3.
Dependence of mammary cancers on hormones
other than oestrogen has been postulated and, of these
hormones, prolactin has stimulated most interest. The
results of cell and tissue culture work (Montassori et al.,
1977) would suggest that a proportion of human breast
cancers exhibit dependence on prolactin and other hormones
in vitro. It is well-proven that experimental rodent cancers
are prolactin dependent, but clinical experience in humans
would indicate that prolactin exerts little influence on
tumour behaviour in vivo. Indeed, McMillan et al. (1977)
have shown that serum prolactin may rise after hypophysectomy
(perhaps due to secretion by residual pituitary stalk),
and yet tumour regression may still occur. The available
data on prolactin and breast cancer have been comprehensively
reviewed by Smithline et al. (1975).
Prom the clinician's viewpoint, it may be considered
that oestrogens are the only hormones which have been
clearly shown to influence the behaviour of human mammary
cancer in vivo. Therefore, the forms of endocrine mani¬
pulation currently practised for the control of advanced
disease are largely aimed either at reducing the amount of
circulating oestrogen available to the tumour cell, or at
"blocking" the interaction of oestrogen with the cell.
■ V»
II. EHDOCRIHE THERAPIES AVAILABLE FOR THE CONTROL OF
ADYAITCSD BREAST CANCER
A. Oophorectomy
The first report of a remission of advanced mammary
cancer induced by endocrine manipulation was made "by
George Beatson in 1896. This was before the advent of
endocrinology as a science; before the nature, and very
existence, ofhormones" was understood; and long before
the formulation of the concept of hormone-dependence of
neoplasms by Huggins and Rous. Beatson's observations of
Ayrshire cattle had led him to believe that the activities
of the mammary glands and of the ovaries were, in some
mysterious way, interrelated. This belief led him,
empirically, to remove the ovaries of two young women with
locally advanced breast cancer. He reported remission of
disease in both cases. Following Beatson's pioneering
reports Thomson (1902), from Edinburgh, published the
results of treating 80 cases of inoperable breast cancer by
means of bilateral oophorectomy. His overall response rate
was 36^. A further early series of 99 cases was reported
by Lett (1905). He found a response rate of 36.4?S.
The operation of oophorectomy then seemed to fall
into disfavour but, following the provision by Huggins and
Rous of a scientific rationale for such a procedure,
interest reawakened and, since 1945> numerous series have
been reported in the literature. The response rates in
some representative series are shown in Table 1. Regrettably,
the response rate of around 36$ reported by Thomson in 1902
and Lett in 1905 has not been significantly improved upon
in any of the subsequent series. The data suggest that in
premenopausal women response rates of around 40$ can be
achieved, but in postmenopausal women the response rate is,
at best, around 15^. Oophorectomy has remained the "first-
line" treatment of choice for the management of advanced
breast cancer in premenopausal women. Over the years,
17
Table 1.
Response rates, complete and partial, to oophorectomy.
(Representative series.)
SERIES Mo. CASES RESPONSE(%)
Lett, 1905 99 36
Block, 1960 60 40
Dao, 1972 (premenopausal) 259 40*
Dao, 1972 (post " ) 90 15*
Veronesi, 1975 639 30*
Henderson, 1900 1674 33*
* Indicates review of collected series.
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however, a gamut of other "endocrine manipulations" has
been added to the clinician's armamentarium.
B. Adrenale ctomv
Scott and Vermeulen (1942) showed that adrenalectomy
produces a profound fall in urinary sex steroids and it soon
became recognised that the adrenal glands are a source,
additional to the ovaries, of oestrogens (Bao, 1955). It
was recognised as early as the 1940's that, by causing a
reduction in circulating oestrogens, adrenalectomy might be
of benefit in cases of advanced breast cancer. However,
until the development of effective glucocorticoid replacement
therapy (Huggins and Bergenstal, 1952) the procedure was
considered too hazardous. Since the early 1950's, many
series of the results of adrenalectomy have been reported.
The results of some representative series are given in
Table 2. The quoted response rates of 30/6 to 4C$ are
similar to those achieved with oophorectomy; ana adrenal¬
ectomy remains a widely practised treatment in postmenopausal
or oophorectomised women with advanced disease. The
procedure is of particular value in producing a further
period of remission in patients who previously responded
to oophorectomy (Pearson et al., 1955)-
0. Pituitary Ablation
The beneficial effects of hypophysectomy in human
breast cancer were demonstrated, independently, in Sweden
and in America in the 1950*3 (Luft and Olivecrona, 1953;
Pearson and Ray, 1959). Evidence from experimental animal
work had suggested that the pituitary hormones, prolactin
and growth hormone, were implicated in tumour growth. This
had raised hopes that response rates to hypophysectomy
would exceed those to adrenalectomy by virtue of the ablation
of these additional hormones. However, the American Medical
Association (1961) found that response rates to the two
19
Table 2.
Response rates, complete and partial, to adrenalectomy.
(Representative series.)
SERIES No. CASES RESPONSE(%)
Hoggins, 1952 6 33
American Medical Assoc.,196 1 315 32
Dao, 1972 1384 45*
Henderson, 1980 3739 32*
* Indicates review of collects d series.
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procedures were virtually identical and concluded that the
effects on tumour growth of hypophysectomy are due solely
to loss of ACTH. The results of representative series of
pituitary ablation chosen from the literature are presented
in Table 3.
D. Oestrogens
It is a puzzling paradox that pharmacological doses
of oestrogen can produce remissions in those breast cancers
thought to be "oestrogen-dependent". The mechanism of
action is poorly understood but it seems possible that, in
high dosage, oestrogen interferes with cytoplasmic receptor
function in a manner similar to that discussed below with
reference to anti-oestrogens. A second paradox is that
those patients who experience a remission to oestrogen
therapy may have a second remission when the hormone is
withdrawn. Henderson and Canellos (1980) have collated
series totalling 1683 patients treated with high dose
oestrogens and report a mean response rate of 2Sfo to the
initial administration.
E. Anti-oestrogens
Substances which may be regarded as "anti-oestrogens"
may interfere with oestrogen-target cell interaction in a
variety of ways. They may simply block the access of
oestrogen to its cytoplasmic receptor; they may inhibit
translocation of hormone-receptor complex to the cell nucleus;
or they may prevent the initiation of oestrogen-induced synthesis
of DNA, RNA and protein. In hormone-dependent breast cancers,
tumour growth may be regarded as an oestrogen-mediated
phenomenon which can be inhibited by anti-oestrogen3. Legha
and Carter (1976) have suggested that this effect is brought
about, not simply by competition for receptor binding, but
by inhibition of the mechanism for receptor replenishment.
21
Table 3.
Response rates, complete and partial, to hypophysectomy■
(Representative series.)
SERIES No.CASES RESPONSE(%]
Pearson, 1959 218 50
American Medical Assoc. 1961 358 31
Dao, 1972 229 44*
Henderson, 1980 1174 *CDCO
* Indicates review of collected series.
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Three anti-oestrogene are in clinical use for the
control of advanced breast cancer: tamoxifen, clomiphene
and nafoxidine. Results of clinical trials of the three
drugs are presented in Table 4. The response rates to all
three drugs are similar to those attained with the other
forms of endocrine manipulation discussed above. The most
striking advantage of these drugs, particularly tamoxifen,
is the almost complete absence of side effects. "Flare"
and hypercalcaemia may occur, thrombocytopaenia and reti¬
nopathy have been reported, but all are rare. This class
of drug must be regarded as a significant advance in the
humane management of advanced breast cancer.
F. Aminoglutethimide
Aminoglutethimide was developed as a potential
anti-convulsant but this application was abandoned when
the compound's profound adrenal-suppressive effect became
apparent. Its primary mode of action is to block the adrenal
conversion of cholesterol to A? - pregnenolone; it thus
prevents synthesis of all adrenal steroids and effectively
produces what has been termed a "medical adrenalectomy".
In addition, the compound is believed to inhibit peripheral
synthesis of oestrogen and this action may make an important
contribution to its role in the control of breast cancer
(Griffiths et al., 1973). Iu conjunction with glucocorticoid
replacement therapy, aminoglutethimide is gaining acceptance
among clinicians as a valid alternative to surgical adrenal¬
ectomy in the management of advanced breast cancer. A
major surgical procedure in these, often debilitated,
patients is avoided and the side effects of the drug (skin
rashes, drowsiness and nausea) are usually mild and transient.
Henderson and Canellos (1980) have reviewed series totalling
280 cases and report response rates of between 2556 and 5C$.
In a preliminary study from this centre, Mason et al. (/1980)
confirmed the ability of aminoglutethimide to suppress adrenal
steroid (dehydroepiandrosterone sulphate) production and
reported a response rate of 4/20 cases.
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Table 4.
Response rates, complete and partial, to anti-oestrogens.
(Representative series.)
SERIES No.CASES RESPONSE(%)
Legha & Carter, 1976
Clorniphene .
167 28*
Ibid .
Nafo xidine.
198 31*
Ibid.
Tamoxifen.
308 27*
Henderson and Canellos, 1980
Clomiphene
167 28*
Ibid.
Nafoxidine.
283 31 *
Ibid .
Tamoxife n.
504 35*
* Indicates review of collected series.
24
Gr. Miscellaneous Therapies
Androgens, corticosteroids and progestogens have
also been administered to cases of advanced breast cancer.
The mode of action of these agents is not yet fully elucidated
but corticosteroids and progestogens probably mediate their
effects via adrenal and ovarian suppression respectively.
Henderson and Canellos (1980) have reviewed the available
data on these therapies and report mean response rates of
2\rfo in 2250 cases treated with androgens; 25a/» in 508 cases
treated with progestogens and 23/S in 589 cases treated with
corticosteroids. Prolactin antagonists have also been tried
in cases of advanced disease and Dickey and Minton (1972)
claim that L-dopa can produce, at least, a subjective
response in some cases.
The Present Statu3 of Endocrine Therapy
More than 80 years have now elapsed since Beatson
first demonstrated the effectiveness of endocrine ablation
in some cases of advanced breast cancer. Although the number
of "endocrine manipulations" available to the clinician has
increased, it is regrettably apparent that the response
rate of 36/& achieved by Thomson and by Lett in the first
decade of this century has not been improved upon. It must
also be remembered that, as far as is known, no cure of
advanced breast cancer has ever occurred and that the best
that can be achieved with any currently available treatment
i3 a temporary disappearance of all overt disease. More
often, the remissions achieved are only partial, and may be
poor compensation for the side effects of treatment. The
present status of hormonal therapy for advanced breast
cancer is that approximately a third of patients will
obtain a remission, usually only partial, and always only
temporary, from whatever form of "manipulation" is employed.
This compares with an overall response rate of around 5C$
for currently available cytotoxic regimes (Brunner, 1978).
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Clinicians have long been aware that it is inhumane
to subject patients to major endocrine ablations, with all
their attendant problems, on the basis of a 30^ chance of,
at best, a temporary remission. The dilemma of patient
selection has, in part, been solved by the advent of the
medical endocrine manipulations, the effects of which are,
at least, reversible if therapy fails. Nevertheless,
clinicians and laboratory scientists have been aware of the
need for, and have energetically sought, a means of ore-
dieting which patients comprise the 30ffo who will respond
to endocrine treatments. Such a predictor would save the
remaining 70fi from undergoing ineffective therapies and
enable them to receive cytotoxic agents at an earlier stage
in their disease, unprejudiced by the effects of prior
endocrine ablation.
The potential value of an accurate index of hormone-
dependence in the management of advanced breast cancer has
been emphasised in the foregoing discussion. Such an index
would also be applicable to the management of early disease
now that the value of adjuvant systemic therapy at the time
of primary local treatment is gaining acceptance. A reliable
predictive index would enable the most appropriate mode of
adjuvant therapy (endocrine or cytotoxic) to be selected
for the individual patient.
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III. THE PREDICTION OF RESPONSE TO ENDOCRINE THERAPY IN
ADYAITCED BREAST CANCER
A. Clinical Criteria
The available data concerning the relationships
between various clinical parameters and likelihood of
response to hormonal therapies have been comprehensively
reviewed by Fairgrieve (1965). A brief summary of his
findings, together with additional data from the more recent
literature, are presented here.
a) Site of Metastases
Fairgrieve quoted several series indicating that
metastases in bone are more likely to respond to hormonal
measures than those in other sites. Other workers felt,
however, that response is an "all or none phenomenon" and
that consideration of disease site is valueless in the
prediction of response. In a more recent analysis of
clinical predictors of response, Barlow and Meggitt (1968)
found that none of the features examined (including disease
site) was sufficiently strongly related to response to
make prior selection for oophorectomy or adrenalectomy
clinically feasible. Similarly, Singhakowinta et al. (1974)
described a selection procedure for adrenalectomy based on
clinical features and concluded that although metastases
in viscera were relatively unlikely to respond, clinical
indices were insufficiently precise for practical use.
Henderson and Canellos (1980) collated data from
several series totalling 563 patients with metastases in
bone and 203 with liver metastases. They reported a mean
response rate to adrenalectomy or hypophysectomy of 38$ in
those with bone metastases but of only 13$ in those with
liver metastases. However, the response rates from the
various series of cases with liver metastases ranged from
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0 to 50/&. These more recent data again indicate that the
relationship between disease site and likelihood of response
is insufficiently precise to allow exclusion of individual
patients from consideration for endocrine therapy.
b) Age and Menstrual Status
Since the earliest reports, it has been recognised
that the benefits of oophorectomy are largely restricted
to premenopausal women. However, the relationships between
menstrual status, or age, and response to the other endocrine
ablations has proved more controversial. At the time of
Pairgrieve's review (1965), it was thought that these
factors did have a bearing on response; the evidence seeming
to suggest that patients aged over 60 responded rather
poorly to either adrenal or pituitary ablation, and that
premenopausal women responded rather better than those
past the menopause.
Henderson and Canellos (1980) concur with the view
of Dao (1972) that, in general, younger premenopausal and
younger postmenopausal women have a lower response rate to
ablative therapies than do older women of equivalent meno¬
pausal status. They conclude, also, that for most forms
of endocrine therapy, postmenopausal women respond more
often than premenopausal. This last conclusion is at
variance with that reached by Pairgrieve in 1965, but,
being founded on an additional 15 years of clinical exper¬
ience, is possibly nearer the truth.
c) Response To Previous Therapy
Much clinical evidence exists to suggest that a
previous response to oophorectomy augurs well for response
to further endocrine ablations. Pearson and Ray (1960)
showed that 21 of 25 premenopausal women who had responded
to oophorectomy and then relapsed, subsequently responded
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to hypophysectomy. Conversely, 27 of 29 who had failed to
respond to oophorectomy also failed to respond to hypophy-
sectomy.
More recently, the response to pharmacological
methods of endocrine manipulation has been used in selecting
patients for surgical ablation. Newsome et al. (1978)
treated 13 patients with amlnoglutethimide for 3 months
and then performed adrenalectomy on all 13- The 8 patients
who had responded to aminoglutethimide also responded to
adrenalectomy. The remaining 5 patients failed to respond
to either treatment. The response rate of 8/13 in this
small series is, of course, considerably higher than that
generally reported for either aminoglutethimide or adrenal¬
ectomy. This would suggest that some element of pre¬
selection was operative and, perhaps, the predictive value
of aminoglutethimide-response would be less striking in a
more general series. A similar approach has been applied
to the prediction of oophorectomy response, using medroxy¬
progesterone as the ovary-suppressive agent.
Information concerning response to previous hormonal
therapy is, therefore, of clinical value in selecting
patients for subsequent ablations. However, such information
is not always available, and, should the practice of adjuvant
oophorectomy become more prevalent, knowledge of response to
previous oophorectomy may become a rarity. Even when
available, information regarding oophorectomy response is
not infallible in the prediction of subsequent response.
Well-documented cases exist where response to subsequent
ablative therapy has followed apparent failure to respond
to oophorectomy (Kennedy et al., 1956; Cade, 1958;
Randall, 1960).
d) Disease-Free Interval
The interval between initial treatment and the
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appearance of local recurrence or metastases, the disease-free
interval (DPI), is regarded as an indicator of the inherent
"aggressiveness" of a particular tumour and has "been eval¬
uated as a predictor of treatment-response and of prognosis.
Pairgrieve (1965) reviewed the evidence of several groups
and concluded that cases with a long DPI are more likely
to respond to endocrine therapies than those where the
interval is short. More recently, Henderson and Canellos
(1980) reviewed series totalling 2586 patients treated by
adrenalectomy or hypophysectomy. They found an increasing
response rate with increasing length of DPI. The mean
response rate was 3C$ in cases with a DPI of less than
2 years and rose to 56f^ in cases with a DPI of greater
than 5 years. Patients who initially presented with advanced
disease (zero DPI) formed an intermediate group, with a
response rate of 38^. This is probably because these cases
were derived from 2 populations, those with very "aggressive"
disease and those with slow-growing disease which they had
been able to ignore for a prolonged period.
B. Laboratory Criteria
Clinical features, in particular DPI and the nature
of response to previous therapies, can be of value in pre¬
dicting response to endocrine manipulation. However, no
one clinical feature, nor any "index" derived from a com¬
bination of such features, can predict, with a clinically
useful degree of precision, the response of an individual
patient. Response to oophorectomy might be regarded as
sufficiently accurate to allow for the selection of patients
for subsequent ablations, but such information is decreas-
ingly commonly available with the increasing popularity of
adjuvant oophorectomy.
A major advance in the endocrine treatment of advanced
breast cancer has been the development of pharmacological
agents, such as aminoglutethimide, which can be used to
predict response to, or even replace, the major surgical
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ablations. Nevertheless, the ability to pre-select likely
responders to hormonal therapies, with a precision which
cannot be achieved by consideration of clinical features
alone, would be of immense value in rationalising the
choice of advanced disease, and adjuvant, therapies. With
these aims in view, numerous laboratory investigations
have been evaluated with regard to their value as predictors
of response.
a) Histology Of The Primary Tumour
Eairgrieve (1965) suggested that there was no
correlation between simple aspects of tumour histology
and response to endocrine therapy. More recently, Maynard
et al. (1978) have compared histological grade, not directly
with response to therapy, but with oestrogen receptor (E/R)
status (see below) in 500 primary cancers. They found
that well-differentiated tumours were more likely to possess
E/R than poorly-differentiated ones, but that th8 difference
was only significant in postmenopausal women.
Masters et al. (1978) estimated the elastica content
of tumours by histochemical staining and found a correlation
with E/R activity. In a subsequent report (Masters et al.,
1979) they were able to correlate elastica content with
response to therapy in a series of 51 patients. They
reported a response rate of 50$ in those where elastica
was abundant in the tumour, and of only 15$ iu those where
elastica was absent.
b) Vaginal Cytology
It may be postulated that the success of manipulations
designed to control tumour growth by reducing circulating
oestrogen levels requires that:
1) the tumour cells must have the inherent capacity
to respond to oestrogen
2) sufficient oestrogen must be present in the body
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before therapy to produce an effect on the
tumour cell.
Clearly, if circulating oestrogen levels are minimal before
therapy, then treatments which exert their effects by
diminishing oestrogen production are doomed to failure,
even if the tumour is inherently hormone-sensitive. On
the basis of this simple concept the earliest laboratory
attempts to select patients for endocrine ablation were
designed to ascertain the "oestrogenic status" of the
patient.
Cornification of vaginal epithelial cells, as
observed in smear preparations, is a well-recognised index
of oestrogen activity (Young et al., 1957). There is,
however, no evidence to suggest that pre-operative "oestrogenic
status" assessed by vaginal cytology (or by direct urinary or
plasma assay) is a dominant factor in determining whether
or not a particular patient will respond to ablative surgery.
c) Urinary Oestrogen Sst-imptti nns
Methods of measuring urinary oestrogen excretion
have been available since the early 1950's. Since that
time groups of workers have attempted to correlate pre-
treatment oestrogen excretion with response to subsequent
endocrine ablation. Initially a bioassay technique was
used (Bergenstal et al., 1955) but this was soon super¬
seded by a more reliable and reproducible chemical method
(Bulbrook et al., 1958). In their early studies Bergenstal
et al. (1955) found that oophorectomised women with high
urinary oestrogen excretion had a higher response rate to
adrenalectomy than similar women whose oestrogen excretion
was low. These results could not be reproduced by other
workers and the assay methodology employed was much criticized.
Using the chemical method, several groups (Bulbrook
et al., 1958: Swyer et al., 1961: Palmer and Helmstrom,
1962) failed to identigy a significant relationship between
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pre-treatment oestrogen excretion and response to subsequent
adrenalectomy or hypophysectomy. It seemed, therefore, that
these new chemical methods of assessing "oestrogenic status"
did not fulfil their early promise, and were, in practice,
no more useful than the simple expedient of vaginal cytology.
d) Estimation Of Urinary Adrenal-Steroid Metabolites
Soon after the development of the urinary oestrogen
assays, techniques became available for measuring the
excretion of other steroid hormones. Attempts were made to
correlate the results of these estimations, in various
combinations and permutations, with response to hormonal
therapies. The best known, and most extensively evaluated,
of these permutations was the discriminant function devised
by Bulbrook et al. (1960). The discriminant function, F,
was calculated from the following formula:
F = 80 - 80{j 7-OH-corticosteroids (mg/24 hr)3 +
[jetiocholanolone (jig/24 hr)3
The formula was derived by consideration of the excretory
levels of these steroids found in a group of women whose
subsequent response to endocrine ablation was known.
Positive values of "F" tended to occur in those who responded,
and negative values in those who failed to respond. In the
original series of patients, 13 of 14 "responders" had a
positive value of "F" and 21 of 27 "non—responders" had a
negative value.
Many groups of workers have attempted to confirm
the predictive value of the discriminant function by cal¬
culating its value in series of patients other than those
used in devising it. Unfortunately, confirmation of the
value of the function could not be obtained, and further
studies by Bulbrook's own group indicated that the reliability
of the function was far less than had been hoped. Atkins
(1968) reported on 10 years' experience with the discriminant
function: in a series of 206 patients, treated by adrenal¬
ectomy or hypophysectomy, 104 had positive functions and
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102, negative. The overall response rate in those with
positive functions was 62°/o and, in those with negative
values, 39$. Clearly, the number of responders among those
with negative functions was too high to allow exclusion
of such patients from hormonal treatment. The high overall
response rate in this series suggests an element of pre¬
selection of cases.
e) Steroid Sulnhation
Adams (1964) and Dao and Libby (1968) have shown
that some mammary cancers possess enzyme systems (sulpho-
transferases) which enable them to synthesise sulphated
esters from steroid precursors. Dao (1972) has presented
data from 109 cases treated by adrenalectomy. He reported
a response rate of only 15$ in 46 cases with low sulpho-
transferase activity in the tumour, compared with 73$ in
29 cases where activity was high. Of 30 case3 with unde¬
tectable sulphotransferase activity, there were none who
responded to treatment.
Leung et al. (1973) measured steroid sulphation
in 80 patients with breast cancer. They related the
capacity of the tumour for sulphation to E/R activity
(see below) and found a reasonable correlation. However,
in 22 cases of advanced breast cancer, they found no
correlation between sulphotransferase activity and response
to endocrine ablation.
f) Sex Hormone Binding Globulin (SHBG)
Murayama et al. (1979) measured SHBG levels in the
peripheral blood of 109 women with breast cancer. They
reported a correlation between SHBG level and E/R activity
(see below). They further reported, that in 50 cases treated
by endocrine measures, 20 of 22 with high SHBG levels
responded, compared with only 5 of 28 with low SHBG levels.
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These findings are yet to be reproduced in other centres.
If they are confirmed, then a predictive test which can be
performed on a peripheral blood sample would offer a sig¬
nificant advantage over the tests, to be described below,
which require a tumour biopsy. Preliminary results from
this centre indicate, however, that there is no direct
relationship between plasma SHBG levels and tumour E/R
content (Mason et al., 1980).
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17. OESTROGEN RECEPTOR STATUS
In 1959, Glascock and Hoekstra showed that "oestrogen-
target" tissues, such as uterus and vagina, have a greater
capacity to "take up" oestrogen than do "non-target" tissues
such as kidney or liver. They demonstrated this by in¬
jecting tritium-labelled hexoestrol into goats or sheep
and, after varying time intervals, measuring the radio¬
activity taken up by "target" and "non-target" tissues.
They found a marked, selective localisation of tritium in
the "oestrogen-target" tissues. Jensen and Jacobson (1960)
were able to demonstrate a similar "selective uptake" in
studies using tritiated oestradiol in laboratory animals.
Through these very elegant studies and his subsequent work,
the name of Elwood Jensen has, rightly, become legendary in
the receptor field.
Following this pioneering work, the concept evolved
that this selective uptake of oestrogen is due to the pre¬
sence, in "oestrogen-target" tissues, of intracellular
macromolecules with a high affinity for oestrogen. These
macromolecules have become known as oestrogen receptors (E/R).
Soon after these demonstrations that physiological target
tissues for oestrogen action in experimental animals exhibit
a high affinity for oestrogen, it was postulated that
oestrogen-dependent breast cancers might also possess such a
property. Folca et al. (1961) injected tritiated hexoestrol
into 10 patients with advanced breast cancer prior to sxirgical
endocrine ablation. Portions of tumour and of skeletal muscle
were then removed at surgery and the ratio of tritium-labelling
between the two tissues determined. In 4 patients, tritium-
labelling of tumour far exceeded that of muscle, and all 4
cases subsequently responded to ablation. In the remaining
6 patients, the difference in labelling between tumour and
muscle was much less marked and all 6 failed to respond to
ablation.
Following this in-vivo demonstration that the
oestrogen binding capacity of a tumour seems to predict its
response to endocrine ablation, much energy has been
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directed towards the development of techniques for measuring,
in-vitro. the oestrogen-binding capacity, or E/R content,
of breast cancer biopsy specimens.
A. Techniques Used For B/R Estimations
Most methods for estimating E/R activity in tumour
biopsy specimens employ the same basic principle. A portion
of tumour (around 300 mg in our laboratory) is homogenised
in buffer and centrifuged to yield a tissue extract, the
"cytosol", which contains the E/R , a soluble protein. A
portion of this cytosol is then incubated with radioactive
oestrogen to fill empty E/R sites, i.e. those not already
occupied by endogenous hormone. The radiohormone—protein
complex ("bound hormone") is separated from the unbound,
excess radiohormone by one of several methods and the
amount of radioactivity in the "bound" fraction measured by
scintillation counting.
Most of this "bound" oestrogen will be attached to
E/R, but some will be attached to low affinity, non-specific
binding sites. A measure of this non-specific binding
can be obtained by a refinement of the assay procedure.
An additional portion of tumour cytosol is incubated with
a large excess of non-radio-active oestrogen to "saturate"
the available E/R. Any residual ability of the cytosol to
bind radiohormone is attributable to non-specific binding
which, although of low affinity, is unsaturable.
A brief summary of the various techniques for E/R
assay which are in current use follows. The techniques
differ mainly with respect to the method used for separating
"bound" from "free" hormone after incubation with the
cytosol.
a) Dextran-Coated Charcoal (DCC)
A suspension of dextran-coated charcoal (DCC) is
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added to the cytosol after incubation with hormone. "Free"
hormone is adsorbed to the charcoal which is then removed
by centrifugation. This method was first described by
Korenman and Dukes (1970) and is the basis of the technique
used in many laboratories. The method used in the experi¬
mental work described in this thesis (Hawkins et al., 1977)
is based on this approach.
The currently used technique involves the incubation
of multiple aliquots of cytosol with a fixed mass of radio-
hormone and varying masses of unlabelled hormone. Data
regarding the amount of radiohormone in the "bound" fraction
are obtained for each aliquot and analysed by the method
of Scatchard (1949)» thus yielding a value for the concen¬
tration of E/R (Po) and for the dissociation constant of
binding (Kd). This latter parameter helps to ensure dis¬
tinction between specific and nonspecific binding. The
application of Scatchard analysis to E/R data has been
discussed in detail by Chamness and McGuire (1975) and by
Braunsberg and Hammond (1979).
b) Sucrose Density Gradient (SPG)
This technique is also widely used for the separation
of "Bound", from "Free", hormone. Two aliquots of cytosol
ar8 incubated; one with a single, saturating dose of radio-
hormone, the other with radiohormone plus a vast excess of
unlabelled hormone - for the estimation of non-specific binding.
After incubation, the cytosols are loaded into tubes containing
SDG's and centrifuged, either overnight, using a "swing-out"
rotor, or for 3 hours, using a vertical tube rotor. By
this means, molecules are distributed throughout the SDG,
mainly according to their molecular weights; large molecules
accumulating at the bottom, and small ones at the top of
the gradient. Oestrogen — E/R complex accumulates, therefore,
towards the bottom of the SDG and "free" hormone towards
the top. Fractions are collected from the gradients into
vials of scintillator and the amount of radioactivity in
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each fraction is measured. The amount of E/R in the
cytosol can he derived from the amounts of radioactivity
in the high molecular weight ("bound") fractions of the
"total" and "non-specific" binding tubes.
E/R is found to exist in at least two molecular
forms, sedimenting in the "4S" and "8S" regions of the
gradient."* One advantage of the SDG, rather than the DCC,
approach is that it enables the "4S" and "8S" forms to be
quantitated separately. This separation is useful in the
research field, and, as discussed below, may be of clinical
significance. The SDG- technique is used in many contemporary
laboratories, notably that of Jensen and his co-workers
(Jensen et al., 1975). SDG- analysis was the research tool
used in establishing the molecular characteristics of the
E/R protein (Toft and G-orski, 1966).
c) Miscellaneous Separation Techniques
Other, less widely used, techniques include pre¬
cipitation of the "bound" hormone with protamine sulphate
(Steggles and King, 1970); gel filtration (Godefroi and
Brooks, 1973) arid electrophoresis (Tendings et al., 1975).
B. Clinical Value of E/R Status
The incidence of"E/R-po3itivity"varies between
centres and between methods of assay. Hawkins et al., (1980)
have reviewed this subject and report that 59 - 72/6 of
tumours are designated E/R-positive by DCC analysis,
numerous reports have been published concerning the corre¬
lation between E/R status and response to various forms of
endocrine manipulation. Major reviews on this subject
include those by Henderson and Canellos (1980) and Hawkins
et al. (1980). Some representative figures are presented
in Table 5. Overall, about 40 - 60?6 of E/R-positive tumours
respond to ablation or hormone administration, compared with
*Where "S" refers to the Svedberg unit, a measure of
sedimentation constant.
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Table 5.
E/R-status and response to endocrine therapies.
(Representative series.)
THERAPY. AUTHORS. No. CASES. Response.
(E/R-pos.)
% Response.
(E/R-neg . ) %
□oph orectomy Hawkins
et.a 1.
225 53/91 58 7/134 5
tt Henderson
&Canellos.
90 25/33 76 4/53 7
Adrenalectomy Hawkins
et . a 1.
62 1 3/33 39 0/29 0
Henderson
& Cane 1los.
99 32/66 48 4/33 12
Oestrogens Hawkins
S T. a 3 i a
169 65/105 62 4/64 6
Henderson
&Canellos.
115 37/57 65 5/58 9
Ant i-
oestrogens
Hawkins
et . a 1.
235 74/138 54 14/97 14
tt Henderson
& Canellos .
1 56 59/116 59 2/40 5
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■well under 10% of E/R-negative tumours. One exception to
this generalisation is that Hawkins et al. (1980), in a
review of series totalling 235 cases treated with anti-
oestrogens, found a response rate of 14% in 97 case3 desig¬
nated E/R-negative. However, in their review of 156 cases
treated with tamoxifen, Henderson and Canellos found a
response rate of only 5% in 40 cases designated E/R-negative.
Knowledge of E/R status, as assessed by current
techniques, enables the clinician to spare about 30% of
patients with advanced breast cancer from undergoing value¬
less endocrine therapy. Very few (less than 10%) of these,
the E/R-negative cases, would have responded had they been
so treated. Viewed in another way, E/R status enables the
most appropriate mode of treatment for advanced disease to
be selected in over 65% of cases: the 30% who are E/R-
negative are identified for treatment with chemotherapy,
the 35% who respond to endocrine measures are allocated
to this form of treatment by virtue of their S/'R-positive
status and only 35% of cases, the E/R-positive but non-
hormone responsive group receive "sub-optimal" therapy.
Thus, the "predictive value" of negative E/R status exceeds
90%, but of positive E/R status, is only 40 - 60%.
G. Limitations of E/R Status
E/R status is clearly a significant advance over
clinical criteria and previously evaluated laboratory
parameters in terms of its predictive value. However,
E/R remains far from ideal as a clinical tool. Firstly,
conventional methodology, either DCC or SDG-, is cumbersome,
requiring the use of some 300 mg of tumour. Such a quantity
is often unavailable in patients presenting with a small
primary tumour or with relatively inaccessible metastases,
such as those in bone or liver. For these patients, E/R
status cannot readily be determined to assist in the selection
of appropriate therapy. Secondly, these current techniques
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require the use of radioactive materials and
expensive equipment for homogenisation, centri-
fugation and scintillation counting. Such techniques are
restricted, therefore, to special centres and are unsuitable
for adoption by peripheral hospitals. Thirdly, despite its
advantages over previous predictors of response, B/R status
remains an imperfect predictor for the individual patient,
in that only about 50$ of E/R-positive tumours are endocrine-
responsive. fourthly, the biochemical technique obscures the
heterogeneity of breast tumours by "pooling" the cytosol
from epithelial cells and stroma and, possibly, from E/R-
positive and negative tumour cell populations.
Recently much research has been directed at over¬
coming these limitations of E/R status. On the one hand,
attempts are being made to "stream-line" the techniques
for identification of E/R so that they may be performed
with les3 expense, and on smaller specimens. On the other
hand, independent parameters continue to be evaluated in an
attempt to identify the subgroup of E/R-positive tumours
which will actually respond to endocrine manipulation.
These two approaches to overcoming the limitations of
E/R status will now be discussed.
D. Recent Advances In Techniques for The Identification
Of E/R
a) Conventional Assays On Smaller Samples
Several groups of workers are developing techniques
which require a much smaller mass of tumour than the 300 mg
preferred in our laboratory, but which still involve the
same steps of cytosol preparation, incubation with radio-
hormone and separation of "bound", from "free", hormone.
Such approaches include an assay based on iso electric
focusing (Wrang et al., 1979) and a variant of the DCC
technique (Poulsen et al., 1979). The latter group have
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attempted to determine E/R status in cytosols prepared
from fine-needle aspirates of tumours. They admit, however,
that the "false-negative rate" is unacceptably high, due,
probably, to the low cel.lularity of some aspirates.
b) Immunobi stol ncrjcal Techniques
An alternative to the development of biochemical
techniques "in miniature" as discussed above, is the
application of immunohistological techniques to the identi¬
fication of E/R in histological sections of tumour. Work
is progressing in several centres towards raising an antibody
to the E/R protein. As yet, however, an antibody which will
bind to human tumour E/R is unavailable. All current
immunohistological techniques for the localisation of E/R
depend, therefore, on the use of a labelled antibody to
oestradiol. and thence to an indirect assessment of the
presence of E/R in the tissue.
Pertschuk et al. (1978) described one such technique
in which frozen sections of breast cancers were incubated
with polymerized oestradiol which became bound to any E/R
present. 'The sections were subsequently exposed to sheep,
anti-oestradiol serum and, finally, to fluorescein-conjugated,
rabbit, anti-sheep serum. This system permitted the local¬
isation of bound oestradiol when the sections were examined
by fluorescence microscopy. Control sections, processed to
identify any non-specific fluorescent staining, were
incorporated in the technique. A 95$ correlation with
results of DCC and SDG- techniques was reported using this
system.
Walker et al. (1980) reported briefly on a similar
technique. They incubated frozen sections with non-polymerised
oestradiol and subsequently exposed the sections to rabbit,
anti-oestradiol serum, followed by anti-rabbit gamma-globulin
raised in swine and,finally, to peroxidase-antiperoxidase
complex. This system permitted indirect localisation of
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E/R under the light microscope after staining for peroxidase
using diaminobenzidine. These workers found the number of
positively-staining tumours to be very small. Mercer (1979)
has evaluated both immunofluorescent and immunoperoxidase
techniques for the localisation of B/R. Like Walker et al.,
he used non-polymerised oestradiol for the initial binding
reaction to E/R. An 85"/<> correlation with the results of
DCC assay is reported using these systems.
Eurzon and Sternberger (1978) have described an
immunoperoxidase technique for the identification of E/R
in fixed, rather than frozen, sections. Their method
involves incubation of tissues with oestradiol -prior to
fixation to "protect" the receptor. Subsequently, sections
are exposed to anti-oestradiol serum. The technique is not
applicable, therefore, to the examination of specimens
which have been fixed and stored in the usual way. The
principles of the immunohistological techniques are
illustrated in Figure 1 .
c) Histochemical Teohrnrmea
Despite the apparently excellent agreement of the
results of their immunohistological technique with those of
conventional assays, Pertschuk et al. (1979) published an
"improved" method for the detection of E/R in frozen sections.
This method involved incubation of sections with a conjugate
of oestradiol, albumin and fluorescein. Controls to identify
non-specific fluorescent-labelling, included equivalent
sections co-incubated with an excess of unconjugated
oestradiol, or analogue; and sections incubated with a
conjugate of albumin and fluorescein only. A 927S agreement
with the results of DCC assay wa3 reported using this
system. The authors stated the advantages of this method
over their previous immunohistological system to be the
better availability and reproducibility of the reagents.
Lee (1978) has also examined frozen sections for E/R
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Diagrammatic representations of possible
approaches to E/R identification.
immunohistolo gical
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using a similar conjugate of oestradiol, albumin and
fluorescein. Of 17 tumours examined he found histochemical
evidence of E/R in 15-
Walker et al. (1980) have also evaluated a histo¬
chemical technique. They used a conjugate of oestradiol,
albumin and peroxidase, rather than fluorescein. A good
correlation, in qualitative terms, was reported between the
results of histochemistry and DCC assay. The principles
of the histochemical techniques are illustrated in Figure 2.
The experimental work to be described in this
thesis includes an evaluation of histochemical techniques
based on those of Pertschuk et al. (1979) and of Walker
et al. (1980).
E. Recent Alternatives To E/R Status In The Prediction
O-f* Haq-nrtnqa mo Hlioi-inno 'TVio-rvrr
a) Receutor Quantitation
In current clinical practice, E/R assays are used
to assign a tumour to either the E/R-positive or E/R-negative
category. Treatment decisions are then based on this simple
classification. It has been suggested that a more precise
consideration of the amount of S/R in the cancer cell might
improve prediction. McGuire et al. (1978) reported on over
100 patients in whose breast cancer metastases E/R had been
assayed quantitatively. They divided the tumours into 3
categories on the basis of increasing E/R content and found
response rates to endocrine therapy of 6%, 46% and 81% in
successive categories. Jensen (1975) and Leclercq and
Heuson (1977) report a similar relationship between likeli¬
hood of response and concentration of E/R. However, Hawkins
et al. (1979) found that such a relationship applied only
to premenopausal women.
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t>) Nuclear E/R Assay
It has been postulated that, since E/R must be
translocated to the cell nucleus in order to mediate tumour
growth, identification of E/R within the nucleus might
provide a better indication of hormone-dependence than that
afforded by identification of B/R within the cell cytoplasm.
Several reports (Anderson et al., 1972; Riang, 1977;
Laing et al., 1977; Leake, 1977; Panko and MacLeod, 1978;
Zava and McOuire, 1977) have described the preparation of
nuclear pellets from breast cancers and the assay of these
for E/R. Leake has assayed both cytoplasmic and nuclear
E/R in 250 breast cancers; he found that possessed both.
Data concerning response to endocrine therapy was available
for 43 of the cases. Twenty of 27 cases with both cyto¬
plasmic and nuclear E/R responded; compared with only 1 of
6 with cytoplasmic E/R alone and 1 of 8 with neither.
These data are interesting but are clearly too preliminary
to allow conclusions about the clinical value of nuclear
E/R assay to be drawn.
c) Molecular Form Of E/R
By means of SDG- assay, at least 2 molecular forms
of cytoplasmic E/R, ("43" and "8S"), can be distinguished.
Savlov et al. (1977) have suggested that possession of the
"8S" form is a prerequisite for response to hormone manipu¬
lation, tumours possessing only "43* receptor being unlikely
to respond. The usefulness of this distinction has not been
confirmed by studies carried out in this department
(Ereedman and Hawkins, 1980).
d) Progestogen Receptor
A cytoplasmic receptor for progestogens (Pg/R)
can be identified in oestrogen-dependent tissues, such as
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uterus, by techniques analogous to those used to identify
E/R. Horwitz et al. (1975) postulated that the synthesis
of Pg/R in such tissues is oestrogen-dependent, requiring
that B/R "be "bound to oestrogen, and he "translocated" to
the cell nucleus; i.e. requiring the presence of a
functional E/R. They suggested, therefore, that Pg/R, as
an index of functional B/R, might be a better index of
hormone-dependence than the mere presence of cytoplasmic
E/R.
McGuire et al. (1978) reported on 71 patients in
whose breast cancer metastases both E/r and Pg/r had been
measured. A response rate to hormonal therapies of 83$
was found in cases possessing both E/r and Pg/r, compared
with only 29$ in cases possessing E/r alone. Th83e figures
suggest that the response rate in Pg/r-negative cases is
too high to permit patient selection on this basis. The
experimental work described in this thesis includes an
evaluation of Pg/r as an indicator of hormone-dependence
in rat mammary tumours.
e) Androgen Receptor
Androgen receptors (A/R) have been les3 widely
investigated, with reference to breast cancer, than have
E/R and Pg/R. Persijn et al. (1975) measured A/R in 51
breast cancers. They found that 4 of 6 patients with A/R
in their tumours responded to oophorectomy compared with
none of 3 patients without A/R. They found, however, that
A/R status had no predictive value for response to additive
hormone therapy (ethinyl oestradiol), whereas E/R exhibited
a predictive value for both ablative and additive treatments.
Studies on A/R in breast tumours are in progress in our own
laboratories.
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V. ENDOGENOUS PEROXIDASE
It is postulated that when oestrogen enters a target
cell, it "becomes bound to E/R, is translocated to the
nucleus and activates the genetic material to synthesise
proteins such as Pg/R and further E/R. Another protein
whose synthesis is thought to be induced by oestrogen action
in this manner is an enzyme, peroxidase. The evidence,
from the literature, which indicates that peroxidase might
serve as a marker for a "functional B/R", and which prompted
much of the experimental work described in this thesis,
is reviewed below.
A. Peroxidase As A Marker For A "Functional E/R"
Lucas et al. (1955) reported that the administration
of diethyl stilboestrol or oestradiol-173 to oophorectomies!
rats produced a pronounced peroxidase activity in their
uteri. However, these workers did not view the peroxidase
as a marker for oestrogen-dependence, simply suggesting
that it might serve as a marker for "tissue proliferation".
These early studies indicated that the oestrogen-induced
peroxidase activity might be wholly attributable to an
influx of peroxidase-rich eosinophils. In 1969* however,
Brockelmann and Pawcett were able to demonstrate, by electron
microscopy, that peroxidase activity is induced within
uterine epithelial cell3.
The induction of peroxidase in rat uteri by oestrogens,
and also by anti-oestrogens, was further investigated by
Churg and Anderson (1974), Anderson et al. (1975), Jellinck
et al. (1976) and Jellinck and Newcombe (1977). These
later studies indicated that the peroxidase is truly a marker
for oestrogen action, not simply for tissue proliferation,
nor for a non-specific effect of steroid hormones in general.
Jellinck and Newcombe (1977) were able to demonstrate a
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close relationship between the uterotrophic and peroxidase-
inducing effects of a number of steroids and proposed that
peroxidase assay might be useful as a technique for the
determination of oestrogenic activity of compounds.
Peroxidase was measured in mammary tumours a3 long
ago as 1955, when the enzyme was regarded only as a marker
for tissue proliferation. In that year, Neufeld et al.
were able to demonstrate peroxidase activity in the mito¬
chondria of Walker 256 rat mammary tumour models. The
possibility that peroxidase might serve as a useful marker
for hormone-dependence in mammary tumours was first raised
by Anderson et al. (1975). By means of a histochemical
technique, they showed peroxidase activity to be present in
alveolar cells of growing DMA-induced tumours, but to be
absent from such tumours regressing after oophorectomy.
A further report from the same group (DeSombre et al., 1975)
confirmed these findings in a small number of DM8A-induced
tumours, and, in addition, indicated that peroxidase was
absent from actively growing but ovary-independent rat
mammary tumour models.
A further study in animal tumour models of hormone-
dependent and-independent growth was reported by Lyttle et al.
(1979). They measured peroxidase in a total of 45 mouse
mammary tumours. They found a highly significant difference
in peroxidase levels between the hormone-dependent and
-independent groups, with no "overlap" between the ranges
of values. This suggested that, at least in these experimental
models, peroxidase serves as an ideal marker for hormone-
dependence .
Peroxidase activity was measured in 39 human tumours
by lyttle and DeSombre (1977). They demonstrated a wide
spectrum of activities, 9 tumours having no detectable
peroxidase, and some having very high levels - approaching
those found in uterine specimens. They did not correlate
these findings with either response to endocrine therapy or
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with E/R status. Duffy and Duffy (1977) correlated peroxidase
activity with E/R status in a series of 52 human cancers of
those designated E/R-positive, 78$ had demonstrable peroxi¬
dase, compared with only 20$ of those designated E/R-negative.
3. Molecular Characteristics Of Oestrogen-Induced Peroxidase
The oestrogen-induced,endogenous peroxidase of
oestrogen-target tissues (E.C. 1.11.1.7.) is thought to be
a carbohydrate - containing haem protein, like other mammalian
peroxidases (DeSombre and Lyttle, 1978). The same group
have estimated the molecular weight of mammary "tumour
peroxidase by gel filtration. They obtained a value of
50,000, similar to the M.W. of uterine peroxidase but
significantly less than that of other mammalian peroxidases.
Many groups have undertaken electron microscope
studies to determine the subcellular localisation of the
enzyme. In their studies on rat uterus, Brockelmann and
Fawcett (1969) reported the enzyme to be present in the rough
endoplasmic reticulum and nuclear envelope of epithelial
cells, but to be absent from the G-olgi apparatus. Churg and
Anderson (1974) and Anderson et al. (1975) reported a similar
distribution of the enzyme in uterine epithelial cells, but
found that it was also present in the Golgi. In studies of
DKBA-induced rat mammary tumours, (Anderson et al., 1975 and
DeSombre et al., 1975) and of healthy, lactating rat mammary
gland (Anderson et al., 1975) a similar subcellular distri¬
bution of enzyme was found and also a strongly positive
peroxidase-reaction in the lumens of ducts was noted, suggest¬
ing secretion of enzyme.
Investigation of the time-course of oestrogen-induced,
peroxidase synthesis indicates that the enzyme begins to
appear 4 hours after oestrogen administration, is maximal
at 20 hours and declines thereafter, (lyttle and DeSombre,
1977). Earlier studies had suggested that the enzyme did
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not begin to appear until 12 hours after oestrogen-stimulation
(Brockelmann and Fawcett, 1969) and that its activity was
maximal at 72 hours (Lucas et al., 1955). The half-life
of the oestrogen-induced peroxidase is reported to be around
4 hours (Jellinck et al., 1976).
C. The Physiological Role Of Oestrogen-Induced Peroxidase
The experimental work described above has indicated
that synthesis of peroxidase is induced, in target tissues,
by oestrogen action; and that this enzyme can be "exploited"
as a useful marker for oestrogen action. Groups of workers
investigating this oestrogen-induced peroxidase have postu¬
lated various possible physiological functions for the
enzyme and have attempted to elucidate its biological role.
One theory is that a peroxidase system potentiates
the conversion of oestrogens to phenoxy radicals and their
binding to proteins,(Williams - Ashman & Johnson, 1960;
Williams - Ashman, 1965; Brockelmann, 1969; Jellinck &
Fletcher, 1970; Williams - Ashman & Reddi, 1971). In this
way, the presence of peroxidase, induced by an "oestrogen-
to-receptor-interaction", might serve to catalyse further
binding of oestrogen to its receptor.
Other workers (Klebanoff & Segal, 1960; Jellinck &
Irwin, 1963; Lyttle & Jellinck, 1972; Jellinck & Lyttle,
1972; Jellinck & Lyttle, 1973) suggest that a peroxidase
system is involved in the conversion of oestrogens to
inactive, water-soluble metabolites, thus limiting their
duration of action on the target tissue. The peroxidase-
catalysed conversion of oestrogen to water soluble products
is well documented, and is the basis of an established
assay for peroxidase activity (Jellinck & Newcombe, 1977).
The peroxidases of various body fluids (e.g. saliva,
milk and tears) have been shown to exhibit bactericidal
and virucidal properties (Klebanoff and Luebke, 1965;
Klebanoff et al., 1966; Belding et al., 1970). It may be
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that in the genital tract, also, such a function is of
importance. A final theory is that peroxidase may be
responsible for the "uterine-fluid mediated, sperm-inhibitory
system"described by KLebanoff and Smith (1970) and Smith and
ELebanoff (1970).
D. Techniques For The Assay Of Endogenous Peroxidase
Activity
Endogenous peroxidase catalyses reactions of the
general form:
m2 + H2°2 * E + 2 H20
where IM2 represents a hydrogen donor. The reaction can
be regarded as one with 2 substrates, the hydrogen donor
and the peroxide. The enzyme exhibits a high degree of
substrate specificity with regard to the peroxide, only
hydrogen, acetyl, methyl or ethyl peroxides serving as
substrates. With regard to the hydrogen donor, however,
the enzyme exhibits broad specificity. Many hydrogen
donors which give rise to coloured oxidation products
can serve as substrates, and these can conveniently be used
for the assay of peroxidase activity, as the rate of appear¬
ance of the coloured products can be measured by spectro¬
photometry.
Many hydrogen donors have been described for use in
biochemical assay systems (Maehly and Chance, 1954; Putter,
1974). Putter recommends di-o-anisidine as producing the
most accurate results; however, this compound is carcino¬
genic and guaiacol is, therefore, recommended for most uses.
The first description of the guaiacol reaction for the
assessment of peroxidase activity was made by Lepinois (1899)
and most biochemical studies of oestrogen-induced peroxidase
have employed a guaiacol method based on that of Hi.mmelh.och
et al. (1969). Herzog and Fahimi (1973) described a
colourimetric assay method based on 3,3'-diaminobenzidine
as hydrogen donor and claimed a better sensitivity than can
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be achieved with the guaiacol methods. A very different
approach to the assay of peroxidase activity was used by
Jellinck and Hewcombe (1977). The ability of peroxidase
to accelerate the conversion of (^C) oestradiol to water-
soluble products provided the basis for their system.
A guaiacol method was chosen for the studies described
in this thesis because of its long-e3tablished use, and the
fact that it is the method of choice of other groups working
in closely related fields (Lyttle and DeSombre, 1977; Duffy
and Duffy, 1977; DeSombre and Lyttle, 1978; Lyttle et al.,
1979; Collings and Savage, 1979).
Although the guaiacol reaction is long-established
for the assay of peroxidases, the chemical structure of the
oxidation product is poorly understood. Booth and Saunders
(1956) reported that, probably, more than one compound
results, and that a definite stoichiometric formula cannot
be given. The product, generally known as "guaiacol
dehydrogenation product" has a characteristic orange/brown
colour with an absorbance peak at 470 nm. Measurement
of the increase in absorbance at this wavelength by means
of spectrophotometry enables the peroxidase activity in
solutions under study to be deduced.
Unlike E/R and Pg/R, endogenous peroxidase is not a
component of the soluble cytoplasm of cells, being associated
with the endoplasmic reticulum and nuclear membrane.
Because of the insoluble nature of the enzyme, peroxidase
activity is minimal in the cytosols prepared for E/R and
Pg/R assay. To produce a tissue extract suitable for
biochemical assay of peroxidase, the enzyme activity can
be solubilised by the addition of calcium chloride to the
homogenisation buffer. DeSombre and Lyttle (1978) have
shown that a concentration of 0.5 M calcium chloride
produces optimal peroxidase activity in tissue extracts.
Higher concentrations reduce the specific activity of the
solubilised enzyme, due to increased extraction of other,
"interfering" proteins.
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A histochemical technique for the localisation
of peroxidase has also "been evaluated in this work. The
method chosen measures the ability of endogenous peroxidase
in a frozen section of tissue to catalyse the oxidation of
diaminohenzidine (DAB) to yield a brown reaction product,
visible at the light microscope level. The product in
this reaction is an insoluble, phenazine polymer.
VI.
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CURRENT STATUS OF THE PREDICTION OF RESPONSE TO
ENDOCRINE THERAPY
In this introductory review, I have attempted to
justify the search for a predictor of response to endocrine
therapies: both for the rational, palliative treatment of
advanced breast cancer, and for the selection of adjuvant
therapy in cases of early disease. The historical review
of attempts to predict response brings me to conclude that,
at the present time, E/R status, as assigned by DCC or SDG-
assay, provides the most precise prediction available. The
main limitations of E/R status, as a clinical tool, are
related, firstly to the fact that many B/R-positive tumours
fail, in practice, to respond to hormonal measures and so
a more precise predictor must be sought; and, secondly,
to the fact that the assay methodology is inconveniently
complex, cumbersome and expensive, and thus considered
unsuitable for routine hospital use.
The experimental work described in this thesis has
been aimed at overcoming these 2 limitations of E/R status.
Firstly, a postulated alternative predictor of response,
endogenous peroxidase, has been evaluated in the hope that
it might provide more accurate prediction. Secondly,
histochemical approaches to E/R identification have been
evaluated in the hope of devising a simple system, more
suited to routine hospital use than current techniques.
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PART II
EXPERIMENTAL METHODS
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1. ASSAY OP OESTROGEN RECEPTOR (E/R) ACTIVITY IN
•TISSUE CYTOSOLS
These assays were performed by the method of
Hawkins et al. (1975), incorporating the modifications
described by Hawkins et al. (1977). The method is based
on the original work of Korenman (1963) and Eeherty et al.
(1970).
REAGENTS
1 . Tris Buffer (0.25M Sucrose; 10mM Tris; InsM EDTA;
pH 8.0).
2. Tris - glycerol - monothioglycerol buffer (10/»
glycerol and monothioglycerol in Tris buffer).
3. (2,4,6,7 - "HOoestradiol 17p ("'0 pg/100ul in Tris)
from New England Nuclear Corporation. ( Q Ep)
4. Oestradiol 17B from Sigma. t0^)
5. Dextran/charcoal suspension: 1.5g/l of Norit A
charcoal (Sigma) in dextran, 0.015g/l in Tris.
6. Organic scintillator solution: 21 ml liquifluor
(New England Nuclear Corporation), 10 ml Ethanol,
490 ml toluene.
METHOD
Rat tissues were dissected free from the host
animals,following exsanguination,and kept on ice. Human
mammary tumours were collected, on ice, direct from the
operating theatre. After weighing, tissues were homogenised,
on ice, in the Tris - glycerol - monothioglycerol buffer at
a concentration of 300 mg/ml (rat tissues) or 100 mg/ml
(human tissues) in a plastic tube (Luckham PT/1772) using a
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Silverson homogeniser for 3x15 sec. episodes. The
resulting homogenates were centrifuge! at 25,000 rpm for
45 rain, in an MSB Superspeed 50 centrifuge (rat tissues)
or at 3,200 rpm for 20 min. in an MSB Mistral 6L centrifuge
(human tumours). The supernatant (cytosol) was then removed
with a Pasteur pipette for E/R and Pg/R assay.
This procedure was modified in the case of tissues
from which the centrifugation pellets were subsequently
to be processed for assay of endogenous peroxidase.
Monothioglycerol inactivates peroxidase (DeSombre et al.,
1978), and so was omitted from the homogenisation buffer
and added to the cytosols (at approximately 1 after
separation from the pellets.
Assay tubes for E/R saturation analysis were prepared,
in duplicate. Each tube contained 10 pg of E2 a
variable mass of °E2 (0, 10, 30, 50, 70 and 90 pg). The
volume in each tube was made up to 1 ml with Tris buffer.
Eor the estimation of "non-specific binding", tubes were
prepared containing 1,000 and 20,000 pg of E2.
After mixing of the tubes, 100 pil of the tissue
cytosol under study was added to each. After 30 - 45 min.,
10 pg of C*rf] E2 was added to each of the "non-specific
binding" tubes, giving sufficient time for the °E2 to
"saturate" any E/R in the cytosol. After further mixing,
all tubes were left to incubate, overnight,at 4°0.
The next morning, 0.5 ml of charcoal suspension
was added to each tube, the contents mixed, allowed to
stand for 15 min. at 4°C and then centrifuged at 2,500 rpm
for 10 min. in the MSE Mistral 61 centrifuge. The super¬
natants ("bound" fractions) were then decanted into plastic
vials, each containing 5 ml of organic scintillator. The
vials were heated for 2 hr. to promote disruption of steroid-
receptor complex, and transfer of steroid to the organic
phase of the counting system. All vials were then subjected
to scintillation counting for sufficient time to reduce the
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coefficient of variation of counting to less than 5%«
In addition, duplicate, standard tubes containing
10 pg of [%] 33 in 1.5 ml Tris buffer were processed with
each batch of assay tubes. The contents of these tubes
were transferred directly to counting vials as a measure of
the total amount of [j^EQ E^ available for E/R binding.
The presence or absence of E/R in the cytosol under
study was then determined by inspection of the raw data.
In cases where E/R wa3 seen to be present, the data were
plotted according to the method of Scatchard (1949) to
yield values for the concentration of E/R present (PQ) and
the dissociation contant of binding (^). S/R concentrations
were expressed in fmoles per mg of wet tissue.
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2. ASSAY OF E/R ACTIVITY IN A SOLID - PHASE SYSTEM
Studies into the effects of various forms of
"fixation" or "protein - immobilisation" on E/R activity
required a system for the assay of E/R in a "solid phase".
Such assays were performed by a method based on that of
Lippman and Huff (1976), derived from the original work of
Steggles and King (1970) and Chamness et al. (1975).
. lippman and Huff used their method to measure E/R activity
in protamine - sulphate - precipitated pellets. In the
present work, pellets derived from precipitation with both
protamine - sulphate and acetone were examined.
Eor the protamine - sulphate assay, cytosol was
prepared as for DOC assay and a 200 jul aliquot was pipetted
into each of 7 glass tubes. To each tube was added 200 ^il
of a 1.5 mg/ml solution of protamine sulphate (Sigma) in
Tris buffer. The tubes were mixed, allowed to stand at
0°G for 5 min., centrifuged at 3,200 rpm for 10 min. and
the supernatants removed by suction. The pellets containing
the precipitated E/R activity were then incubated with
10 pg of [~^H~] an<^ varying masses of (0,10,30,50,70,
90, 1000 pg) in a final volume of 200 pil of Tris buffer.
After incubation at 4°C, overnight, the incubation-mixture
was removed by suction and the pellets washed with 3 x 2 ml
of buffer. The pellets, containing any "bound" C H] ~&2>
were then dissolved in 0.5 ml of ethanol and transferred to
vials of scintillator fluid. The amount of E^ bound
to each pellet was determined by scintillation counting
and the data analysed by the method of Scatchard as described
for DOC assay. Each assay was performed in duplicate.
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3. ASSAY OF E/R ACTIVITY IE GLASS-MOUNTED, FROZEN SECTIONS
This technique was used during preliminary investi¬
gations to establish the feasibility of a histochemical
approach to the localisation of E/R. The retention of E/R
activity in glass-mounted, frozen sections after exposure
to various histochemical processes was assessed by measuring
the uptake of Eg, well established as a valid "tracer"
for E/R activity by virtue of its use in EGO and SJDG assays.
Approximately 200 mg of the tissue under study was
cut into cryostat sections of appropriate thickness (4 jum
or 14 jum). The sections were mounted on glass coverslips
(22 mm x 22 mm); approximately 32 coverslips sufficed to
accommodate 200 mg of tissue. After brief air-drying of
the sections onto the glass, fixation, by various means,
could be carried out. The treated coverslips were then
divided between 2 humidifier chambers, the sections in the
first chamber were flooded with a solution of l Bf| Eg
(20,000 cpm/ml) and those in the second chamber with a
similar solution to which had been added an excess (25,000 pg/ml)
of °Eg. The sections were then allowed to incubate with the
steroid for 2 hr. at room temperature. After incubation, the
coverslips from each chamber were transferred to a small rack
in which they could be immersed in various washing or "post-
fixation" media.
At the end of processing, each of the 2 sets of
coverslips was fragmented sufficiently to enable the whole
set to be introduced into a vial of scintillator fluid. The
radio-labelling of each set of frozen sections was then
determined by scintillation counting. E/R activity was
regarded as being present in the frozen sections if the
radio-labelling of those incubated with Sg alone was
well in excess of the radio-labelling of those co-incubated
with °Eg.
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4. ASSAY OF PROGESTOGEN RECEPTOR (Pg/R) ACTIVITY IN
TISSUE CYTOSOIS
These assays were performed by the method of
Hawkins et al. (1980), using Organon 2058 as the progestogen
for receptor binding.
REAGENTS
These were as for E/R assay but was replaced by
tritium - labelled Organon 2058 (|30 Pg) and °E2 by
organon 2058 (°Pg).
METHOD
Assay tubes for Pg/R saturation analysis were
prepared, in duplicate. Each tube contained 100 pg of
[j^eQ Pg and a variable mass of °Pg (0, 50, 100, 200, 500
and 1,000 pg). The volume in each tube was made up to
1 ml with Tris/glycerol buffer. Por the estimation of
"non-specific binding", tubes were prepared containing
5,000 pg of °Pg.
After mixing of the tubes, 200 /EL of the tissue
cytosol under study (prepared as for E/R assay) was added
to each. After 20 min., 100 pg of [j^eQ Pg was added to each
of the "non-specific binding" tubes, giving sufficient time
for the °Pg to "saturate" any Pg/R in the cytosol. After
further mixing, all tubes were left to incubate overnight,
on ice.
The next morning, 0.5 nil of charcoal suspension was
added to each tube, the contents mixed, allowed to stand for
5 min., on ice, then centrifuged at 2,500 rpm for 10 min.
in the MSB, Mistral 6L centrifuge. The supernatants were
transferred to plastic vials of scintillator, counted and the
data analysed as for E/R assay. Pg/R concentrations were
expressed in fmoles/mg of wet tissue.
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5. ASSAY 0? ENDOGENOUS PEROXIDASE ACTIVITY IN
TISSUE EXTRACTS
These assays were performed "by a method "based on
that of Lyttle and DeSombre (1977), which was modified
from the original work of Himmelhoch et al. (1969). The
experimental conditions and reagent concentrations employed
in the assay described here were determined by a series of
preliminary experiments (pages 77-92 ).
REAGENTS
1. 0.5M CaCl2 in Tris/HCl buffer (lOmM; pH 7.2).
2. Guaiacol (O-methoxyphenol) from BDH, 40mM in the
above buffer. Prepared freshly each day.
3. Hydrogen peroxide from BBH, 12.3mM in the above
buffer. The concentration of the H209 solution
was checked daily by measurement of extinction at
240 nm (0.485 - 0.02 with 1 cm light path).
METHOD
Tissues were harvested from the hosts and cytosol/
pellet preparations produced as described with reference to
B/R assay, but with the omission of monothioglycerol from
the homogenisation buffer. The pellets were rehomogenised,
at a concentration of 100 mg/ml (human tissues) or 300 mg/ml
(rat tissues) in the 0.5M CaCl2/Tris buffer to solubilise
any peroxidase present. These homogenates were centrifuged
at 25,000 rpm for 45 min. in the MSB Superspeed 50 centrifuge.
The resulting supernatants were removed with a Pasteur
pipette and assayed for peroxidase activity.
At room temperature, the following reagents were
added to a glass cuvette of 1 cm light path: Guaiacol
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(final concentration 13-3nal-T), hydrogen peroxide (final
concentration 0.41mM) and tissue extract under study
(0.02 to 0.1 ml depending on peroxidase content). The
final volume was made up to 3 ml by the addition of 0.5M
CaCU^/Tris buffer. A second cuvette was prepared as a
"reagent blank" by the omission of tissue extract. The
reaction was commenced by the addition of the tissue extract
and the "initial" rate of reaction measured by the increase
in absorbance at 470 nm, over 3 minutes, between 1 and 4
minutes after starting the reaction.
Peroxidase activities were expressed in Units per g
of wet tissue. One peroxidase unit was defined as the
amount of enzyme required to produce an increase of one
absorbance unit per min. under the assay conditions used.
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6. HIST0CHBMICA1 LOCALISATION OF ENDOGENOUS PEROXIDASE
This technique ±3 based on that described by
Graham and Karnovsky (1966). The techniques of tissue
fixation described by these workers have been simplified
to make the technique more suitable for light, rather than
electron microscopy. (Preliminary studies indicated that
fixation in ethanol rather than Karnovsky's fixative did
• not diminish the peroxidase-staining visible in the rat
mammary tumours under study)
Blocks of rat mammary tumour measuring approximately
5 x 5 x 2 mm were mounted on metal chucks, embedded in
Cryo-M-Bed (Brights), rapidly frozen using "Polar" spray
and cut into 4 jum sections on a Brights' cryostat. The
sections were mounted on gelatine-coated glass slides, to
improve section adhesiveness. The mounted sections were
fixed for 30 min. in absolute ethanol at room temperature.
After evaporation of the ethanol, the sections were flooded
with DAB - solution (prepared by dissolving 5 mg of
diaminobenzidine tetrahydrochloride from Sigma in 10 ml of
0.1 M Tris buffer, pH 7.6 plus 0.33 ml of 1# H202).
After incubation for 10 min. in this solution, the reaction
was arrested by immersing the slides in tap water. The
sections were then briefly counterstained in toluidine blue,
dehydrated through ascending concentrations of alcohol,
cleared in xylene and mounted under coverslips. Control
sections wer9 incubated with DAB solution from which
had been omitted to identify any non-specific staining.
The stained sections were examined, by light
microscopy, for intracellular, brown granules indicative of
the presence of peroxidase, and were scored as follows:
0 : ho peroxidase present.
1 : Peroxidase present in < 50^ of cells.
2 : Peroxidase present in > 5&f° of cells.
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7. SYNTHESIS OF OESTRAEIOL - BSA - FLUORESCEIN MP
BSA - FLUORESCEIN CONJUGATES
Conjugates for the histochemical localisation of
E/R were prepared as described by Pertschuk et al. (1979).
The conjugation procedure was based on the mixed anhydride
method of Erlanger et al. (1957) and aimed to combine
4 mol. of oestradiol (linked at the position) and 4 mol.
of fluorescein per mol. of BSA.
Oestradiol 17J3 hemisuccinate (10 mg; 30 jumoles),
tri-n-butylamine (0.0075 ml; 30 jumoles) and isobutylchloro-
carbonate (0.004 ml; 30 jumoles) were dissolved in 0.5 ml
of anhydrous dioxane and the reaction allowed to proceed
at 10°C for 45 min. BSA (135 mg) was then dissolved in
16 ml of 5O5S aqueous dioxane at pH 9.0 and 10°C and the
above reaction mixture added, in one step, with rapid
stirring. The pH was maintained at 9.0 by the addition of
N. NaOH and stirring continued for 1 hr.
The reaction mixture was then transferred to
dialysis tubing (Tasking)and dialysed for 30 hr. against
PBS, and 30 hr. against distilled water, at 4°C. The
resulting solution was lyophilised to dryness. The yield
of oestradiol-BSA (approx. 10 mg) was redissolved in 16 ml
of 0.1 M. sodium carbonate buffer (pH 9.5) and 1 mg of
fluorescein iso thiocyanate (FITC) added. The mixture was
left at 0°C, for 24 hr. with gentle stirring. The resulting
solution was dialysed against distilled water at 4°C for
72 hr. and again lyophilised to dryness.
The yield of oestradiol-BSA-fluorescein conjugate
was dissolved in 10fo ethanol in PBS at a concentration of
1 mg/ml. This stock solution was further diluted for
histochemistry.
An attempt was made to confirm incorporation of
oestradiol, BSA and PITC into the conjugate by scanning
spectrophotometry (fig. 26 ).
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A conjugate comprising BSA and FITC only was also
synthesised to serve as a control for the assessment of
non-specific staining of tissue sections due to binding
of BSA. BSA (135 mg) was dissolved in 16 ml of sodium
carbonate buffer, 13 mg of FITC was added, the mixture
allowed to react and the product dialysed and lyophilised
as described for the oestradiol-BSA-FITC conjugate.
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8. SYNTHESIS OF QESTRADIOL - BSA - PEROXIDASE (HBP)
CONJUGATES
Horseradish peroxidase (HHP) is a glycoprotein, of
which the carbohydrate moieties are not required for enzy¬
matic activity. Because of this structural property, the
carbohydrate groups can be utilised for conjugation to
various proteins including antibodies and albumin. HHP can
be visualised by histochemical staining and can, therefore,
serve as a tracer for such proteins in tissue sections.
Two conjugates of HHP with oestradiol, via BSA, have been
prepared for use in the histochemical detection of E/R as
described by Walker et al. (1980).
A. Conjugation By The Method Of Nakane and Kawaoi (1974)
In this technique, the addition of sodium periodate
to HHP brings about conversion of carbohydrate groups to
aldehydes which can then react with protein to form
"Schiff's bases". Eluoro-dinitrobenzene (FDNB) i3 added
to the reaction mixture in an attempt to prevent "self-
coupling" and the formation of peroxidase polymers. By
this method it is aimed to combine 33 moles of oestradiol
(linked via the Cg position) and 2-4 moles of HHP per
mole of BSA.
HHP (type IY from Sigma), 10 mg, wa3 dissolved
in 2 ml of freshly prepared 0.3 M sodium bicarbonate solution
at pH 8.1. To this solution was added 0.2 ml of a 1%
solution of 1-fluoro-2,4,dinitrobenzene (FDNB) from Sigma
in ethanol. The reaction was allowed to proceed for 1 hr.
at room temperature, with constant stirring. To the reaction
mixture was then added 2 ml of a 0.05 M solution of sodium-M-
periodate (Sigma) in distilled water; mixing was continued
for a further 30 min. at room temperature. During this time
the mixture was seen to change to a yellow-green colour,
indicative of the formation of aldehydes.
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The reaction was then arrested by means of the
addition of 2 ml of 0.16 M ethylene glycol in distilled
water. Following this addition, mixing was continued for
a further hour. The reaction mixture was then transferred
to dialysis tubing (Visking) and dialysed overnight against
2 x 2 L of sodium carbonate buffer (0.01 M; pH 9.5) at
4°C.
The reaction mixture (comprising aldehydes of HRP)
- was then removed from the dialysis tubing and 5 mg of
oestradiol-6-0-carboxymethyloxime-B3A (from Steraloids,
containing 35 moles of steroid per mole of BSA) added, by
sprinkling with rapid mixing. After dissolution of the
protein-steroid conjugate, gentle mixing was continued for
3 hours at room temperature. This reaction resulted in
formation of a "Schiff's base" which was stabilised by the
addition of 5 mg of sodium borohydride (Sigma). Following
this addition, the mixture was allowed to stand for 3 hours
at 4°C.
The reaction product was then dialysed against
3 x 2 L of PBS at 4°C over a period of 12 hours. The
product was then applied, in 1 ml aliquots, to an
85 x 1.5 cm column of Sephadex G100 equilibrated with PBS.
Fractions (1.5 ml) were collected and the absorbance of each
fraction at 280 nm measured using an SP200 ultraviolet
spectrophotometer. The fractions forming the first peak
(see fig. 3) were pooled, and were taken to comprise the
yield of oestradiol-BSA-HRP conjugate. The remaining
fractions, containing residual, unconjugated BSA-oestradiol
and HRP were discarded. The yield was frozen in 1 ml
aliquots and stored at -20°C for subsequent use.
B. Conjugation Bv The Method Of Avrameas and Ternvnck (1971)
In this method, glutaraldehyde rather than periodate
is vised to form aldehyde groups with HRP for reaction with
proteins. The spacial configuration of the glutaraldehyde
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Figure 3.
Elution pattern of 6-keto-oestradiol-BSA conjugated with
horse-radish peroxidase. Chromatography was carried out on
a 85x1.5 cm. column of Sephadex, flow rate approx. 10ml./hr.
Fractions 20 to 25 were pooled as representing the yield--'
of oestradiol-BSA-peroxidase conjugate.
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derivative of HHP is, reportedly, such that "self-coupling"
and thus polymer formation is minimised. By this method,
it is aimed to combine 33 moles of oestradiol and 1 mole of
HHP per mole of BSA.
HEP (type IY from Sigma), 10 mg, was dissolved in
0.2 ml of 0.1 M phosphate "buffer, pH 6.8, containing 1 .25%
glutaraldehyde. The solution was allowed to stand for
18 hr. in a cool room and was then filtered through a
"60 x 1.2 cm column of Sephadex G—25 equilibrated with
0.15 M NaCl. The brown fractions, containing the "activated"
peroxidase were pooled and were concentrated to 1 ml by
transferring to a length of dialysis tubing and immersing
in Sephadex powder.
To the concentrated solution was added 1 ml of
0.15 M HaCl containing 4 mg of 17J5-oestradiol-6-0-
carboxymethyloxime-BSA (Steraloids), followed by the addition
of 0.1 ml of 1 M carbonate-bicarbonate buffer, pH 9«5»
After 24 hours at 4°C, 0.1 ml of 0.2 M solution of lysine
was added and the mixture allowed to stand for an additional
2 hr.
The preparation was then extensively dialysed against
several changes of PBS at 4°C and was again concentrated to
a small volume using Sephadex. The product was filtered
through a 100 x 1.2 cm column of Sephadex G-200 and the
absorbances of the resulting fractions at 280 nm (protein
maximum) and at 430 nm (peroxidase maximum) determined.
The fractions comprising the main peak (Figure 3a) were
pooled and were again concentrated to a volume of
approximately 4 ml for histochemical use.
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Figure 3a.
Elution pattern of 6-Keto-oestradiol-BSA conjugated with
horseradish peroxidase by the method of Avrameas 8 Ternynck.
Chromatography was carried out on a 100x1.2cm. column of
Sephadex G200.
The up.per line indicates absorbance at 280 nm. (protein
maximum) and the lower line represents absorbance at 430nm.
(peroxidase maximum). Fractions comprising the main peak
were pooled as representing the yield of conjugate.
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9. HISTOCHBHICAL METHOD FOR THB DET3CTI0N 0? E/R
USING- FLUORESCEIN TRACBR
This technique was described by Pertschuk et al.
(1979) and has been used by the author in an attempt to
reproduce the results described by these workers.
Frozen sections (4 /um) of the tissue under study
were cut using a Bright's cryostat. The sections were
mounted on gelatin-coated slides and allowed to air-dry
briefly to ensure adhesion of the sections to the slides.
Serial sections were then incubated in a humidifier chamber,
at room temperature, for 2 hr. in each of the following
solutions:
1. Oestradiol-BSA-fluorescein (50 jug/ml) in
PBS containing 1C$ ethanol.
2. The "control" conjugate, BSA-fluorescein, also
at a concentration of 50 jug/ml.
3. Oestradiol-BSA-fluorescein (50 jug/ml) plus an
excess of a competitive "receptor-blocker",
CI628 (100 Ag/ml).
Approximately 3 drops of the appropriate solution was needed
to cover each section.
After incubation, excess conjugate solution was
rinsed off with PBS from a wash-bottle. The sections were
then fixed by immersing for 10 min. in a mixture of equal
volumes of ethanol and acetone. Following fixation the
sections were washed for a total of 30 min. by immersing
in 3 changes of PBS. After a final rinse in distilled water
the sections were mounted in buffered glycerol (7-8 parts
PBS, 2-3 part3 glycerol), under coverslips for fluorescence
microscopy.
The sections were viewed using a Zeiss large research
microscope under incident UV light using tube head filter no. 53 •
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10. HIST0CHBMIGAL METHOD FOR THE D2TECTI0I-T OF E/R USING-
PEROXIDASE TRACER
This technique was described by Walker et al. (1Q80)
and has been used by the author in an attempt to reproduce
the results described by these workers.
Frozen sections (4 tun) of the tissue under study
were cut using a Bright's cryostat. The sections were
mounted on plain glass slides and allowed to air-dry
briefly to ensure adhesion of the sections to the slides.
The sections were then fixed by immersing in acetone, at
room temperature, for 4 min. Serial sections were then
incubated in a humidifier chamber, at room temperature,
for 2 hr. in each of the following solutions:
1 . 1 7-JB-oestradiol-6-0-carboxymethyloxime-BSA-
horse radish peroxidase in PBS at a dilution
of between 1/8 and 1/20 of the concentration
obtained at synthesis. (The required dilution
was determined empirically by examination of
preliminary sections).
2. A similar solution of conjugate plus an excess
of a competitive "receptor blocker", tamoxifen
or diethylstilboestrol in saturated solution.
After incubation, excess conjugate solution was
rinsed off with PBS from a wash bottle and the slides then
extensively washed in 3 changes of PBS for a total of 30 min.
In order to visualise any peroxidase-labelling of the
sections, they were incubated with a solution of diamino—
benzidine plus hydrogen peroxide (see method 6), washed
and counter-stained with haematoxylin. The sections were
then dehydrated, cleared and mounted as described in
method 6 and viewed under the light microscope.
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PART III
RESULTS OP STUDIES CONCERNING
PEROXIDASE AS A MARKER FOR HORMONE-DEPENDENCE
&
THE HISTOCHEMICAL LOCALISATION OF OESTROGEN RECEPTORS
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PRELIMINARY EXPERIMENTS TO ESTABLISH A BIOCHEMICAL
ASSAY FOR PEROXIDASE ACTIVITY
A. Determination Of Optimal Substrate Concentrations
The kinetics of enzyme-catalysed reactions are such
that, at low substrate concentrations, the initial rate of
* reaction, v, is directly related to substrate concentration,
[V]. At a certain, higher substrate concentration, QQ, all
the available enzyme is "saturated" with substrate and the
maximum initial velocity, V, for those reaction conditions
(i.e. temperature, pH, enzyme concentration) is reached.
When the initial rate of such a reaction is being used as
a measure of enzyme activity it is desirable that substrate
concentrations should exceed [jsT] since in these circum¬
stances the rate of reaction is uninfluenced by minor
changes in substrate concentration and is a true reflection
of the amount of enzyme present. Preliminary experiments
were performed to determine appropriate substrate concen¬
trations, according to this principle, for the assay of
peroxidase.
The assay conditions were as described in Method 5,
but the cuvette mixture comprised a fixed concentration of
HRP (equivalent to 20 jul of a 0.05 mg/ml solution in a
final volume of 3 ml) and variable concentrations of sub¬
strates (guaiacol and H?02). Eor determination of the
optimal concentration of guaiacol, the H?02 concentration
was maintained at 0.41 mM and six concentrations of guaiacol
(equivalent to 0.1 - 2 ml of a 40 mM solution in a final
volume of 3 ml) were tested. For determination of the
optimal concentration of H202, the guaiacol concentration
was maintained at 13.3 mM and six concentrations of H?02
(equivalent to 0.01 - 0.2 ml of a 12.3 mM solution in a final
volume of 3 ml) were tested.
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RESULTS
a) Optimal Concentration Of G-uaiacol
The initial rate of reaction for each concentration
of guaiacol tested is shown in .Figure 4. The initial rate
increased with increasing concentration of guaiacol to a
maximum at a concentration equivalent to 0.5 ml of the
'stock solution in a final volume of 3 ml. Thereafter,
further increases in concentration of guaiacol failed to
cause any increase in the rate of reaction, indicating
saturation of the enzyme with substrate. A volume of
1.0 ml of 40 ml'I guaiacol (equivalent to a working concen¬
tration of 13.3 mM), which lay well onto the "plateau"
region of the curve, was selected for the routine assay.
The same data plotted by the method of Lineweaver
and Burke (1934)» to yield a straight line, are shown in
Figure 5* A value for the Michaelis constant (K ) for
horseradish peroxidase with guaiacol as substrate was
derived from this graph. The value of Em was equivalent
to a concentration of 1.5 mM guaiacol.
b) Optimal Concentration Of H2O2
The initial rate of reaction for each concentration
of H2O2 tested is shown in Figure 6. The presence of a
"plateau" region on the curve, within the range of concen¬
trations of H2O2 tested, was not as evident as on the
curve for guaiacol. A quantity of 0.1 ml of 12.3 mM H2O2
(equivalent to a working concentration of 0.41 mM) was
selected, somewhat empirically, for the routine assay.
The same data plotted according to Lineweaver and
Burke (1934) are presented in Figure 7. From this graph, a
value for with respect to 0.41 mM was derived.
v
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Figure 4.
Initial rate of peroxidase-catalysed reaction with
varying concentrations of substrate (guaiacol).
Each symbol represents the value obtained in a single
assay.
The double circle indicates the concentration chosen
for the routine assay.
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Figure 5.
Lineweaver-Burke plot of data in fig.4.
v = Initial rate of reaction ( absorbance units / min.)
(s) = concentration of guaiacol expressed as mis. of a
40mN. solution in a final cuvette volumeof 3 mis.
Km calculated from this graph = i.SmM. guaiacol.
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Figure 5.
Initial rate of peroxidase-catalysed reaction with
varying concentrations ot substrate C ^2^2 ^"
Each symbol represents the value obtained in a single assay.
The double circle indicates the concentration chosen
for the routine assay.
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Figure 7.
Lineweaver-Burke plot of data in fig. 6.
v = Initial rate of reaction in absoroance units / mm.
(s) = Concentration of expressed as mis. of a
12.3 mM. solution in a final cuvette volume
of 3 mis.
k calculated from this graph = 0.41 mPI. Ho0n.
m 2 2
\
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B. Determination Of Optimal Method Of Measuring;
Initial Rate Of Reaction
This assay system is based upon the principle that
enzyme activity is directly proportional to the "initial
rate of reaction" under constant reaction conditions. The
rate of reaction is reflected by the rate of appearance of
the coloured reaction product (guaiacol dehydrogenation
_product) which is, in turn, reflected by the rate of increase
in absorbance at 470 nm. It is impossible, in practice,
to measure what is truly the initial rate of reaction, as
mixing of the cuvette contents and manipulation of the
spectrophotometer take a finite period of time. An attempt
has been made to determine the method of assessing "initial"
rate of reaction which, in practise, gives the best correlation
with peroxidase activity.
Using the assay conditions and reagent concentrations
as described in Method 5, six different concentrations of
horseradish peroxidase (0.02 ml to 0.12 ml of a 0.005 mg/ml
solution) were assayed. For each of the six concentrations
the absorbance at 470 nm was measured at one minute intervals
from 0 to 5 minutes after starting the reaction. Using
these data 5 different assessments of "initial" rate of
reaction were calculated for each HHP concentration:
1. Increase in absorbance from 0 to 1 minute.
2. Mean increase per minute from 0 to 5 minutes.
p. Mean increase per minute from 1 to 4 minutes.
BPSUITS
The time course of change in absorbance is shown
for each of the six concentrations of HHP studied in
Figure 8. These curves show that for ail the concentrations
of HHP, the rate of reaction was linear between 0 and 5
minutes.
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In figure 9, the 3 different assessments of "initial"
rate of reaction for each of the 6 HHP concentrations are
presented. Study of the graph reveals that Method 3
(i.e. mean increase in absorbance per minute from 1 to 4
minutes after starting the reaction) best approached a
linear relationship between HRP concentration and initial
rate of reaction. This method was, therefore, selected
for the routine assay system.
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Figure 8.
Absorbance / Time graphs for each of 6 concentrations
of HRP. Concentration is expressed in terms of mis.
of a 0.005 mg/ml. solution of HRP. in a final cuvette
volume of 3 mis.
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Figure 9.
Initial rate of reaction ( absorbance units/min. )
calculated In 3 different ways for each of 6 concentrations
of HRP.
Each symbol indicates the result of a single assay.
• = Increase in absorbance/min. calculated from 0-1 min.
o » " " " " 0-3 min.
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C. Validation Of Assay Using: Known Concentrations Of
HHP And Uterine Peroxidase
Further experiments were performed to confirm the
existence of a linear relationship "between "initial rate
of reaction" and ensyme concentration for both horseradish
and uterine peroxidases over the range of concentrations
likely to be encountered in subsequent studies. Seven
concentrations of HHP (from 0.01 - 0.04 ml of a 0.05 mg/ml
solution in a final volume of 3 ml) were assayed under the
standard conditions. Similarly, eight concentrations of
an extract prepared from rat uterus were examined.
RESULTS
The relationships between "initial rate of reaction"
and ens3/me concentration for HHP and for uterine peroxidase
are presented in Figures 10 and 11. In the case of HHP,
a linear relationship held throughout the range of concen¬
trations tested. For the uterine extract, the relationship
was linear up to a working concentration of approximately
37= extract, equivalent to a volume of 0.09 nil of extract
in a cuvette volume of 3 ml.
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Figure 10.
The relationship between initial rate of reaction, as
measurea under routine assay conditions, and known
concentrations of HRP.
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CONCENTRATION of UTERINE CYTOSOL
IN CUVETTE1 MIXTURE (°/o).
Figure 11.
The relationship between initial rate of reaction, as
measured under routine assay conditions, and known
concentrations of rat uterine extract.
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D. Determination Of The Precision Of The Assay
A study was undertaken to determine the intra-
assay precision of the peroxidase assay under the chosen
conditions (Method 5). Six aliquots (0.06 ml) of a
0.005 mg/ml solution of HRP were assayed, in succession,
on the same day and using the same reagent preparations,
"by the routine method.
RESULTS
♦
The "initial rates of reaction" were as follows:
0.148, 0.142, 0.147, 0.165, 0.158, and 0.169.
The assay precision was calculated from these data using
the formula:
^ . . standard deviation _ «Precision = x IOO70
mean
The intra-assay precision was found to be 6.7
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E. Determination Of The Storage Properties Of Tissue
Peroxidase
Since it was not always possible to assay tissues
immediately after removal from the hosts, such tissues
were stored in liquid nitrogen until a convenient time for
assay. A preliminary study was undertaken to investigate
the stability of tissue peroxidase (from rat uterus) upon
storage in liquid nitrogen. Peroxidase was extracted from
a rat uterus as described under Method 5. Aliquots of this
extrapt were frozen in liquid nitrogen and removed for assay
after various periods of storage: 0, 2, 7, 16 and
33 days.
RESULTS
The peroxidase activity of the uterine extract,
expressed in units/g of parent tissue, after a variable
storage period is shown in Figure 12. In the fresh extract,
peroxidase activitjr was 95 U/g. Activity apparently fell
to 85 U/g after 2 days of storage but longer periods of
storage resulted in no further diminution of activity,
suggesting that tissues can be stored, in this x-ray, with
little or no loss of peroxidase activity.
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Figure 12.
Peroxidase activity detectable in aliquots of a rat
uterine extract after various periods of storage in
liquid nitrogen.
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II. RELATIONSHIPS BETWEEN LEVELS OF PEROXIDASE, S/R AND
Pg/R IN HEALTHY RAT TISSUES
A study was made of the three postulated markers
for hormone-dependence (peroxidase, E/R and Pg/R) in a range
of healthy tissues of the rat. The following tissues were
selected for study to provide a range of classical oestrogen-
target and non-target tissues: uterus and mammary gland
excised from animals in various reproductive states, liver,
kidney, prostate, testis, lung, spleen and erythrocytes.
The tissues were harvested from the host animals, extracted
and assayed for peroxidase, E/R and Pg/R as described under
the appropriate "Methods".
RESULTS
The levels of peroxidase detected in the 1 5 tissues
studied are presented in ascending order in Figure 13.
The levels of E/R and Pg/R in the corresponding tissues are
also included for comparison. Peroxidase was detectable in
all tissues examined with the exception of liver and kidney.
In peroxidase-positive tissues, the range of activities
was very wide, from 0.1 u/gm in lactating mammary gland to
95 u/gm in uterus during oestrus.
S/R was found to be even more widely distributed
than peroxidase, being absent only from erjrthrocytes. In
those tissues in which S/R was present, levels ranged from
0.2 fmoles/mg in mammary gland during oestrus to 35 fmoles/mg
in the uterus of a lactating animal.
Pg/R was much less widely distributed, being detect¬
able only in uterus, lung and kidney. Levels were relatively
low (0.72 and 1.32 fmoles/mg) in lung and kidney, but ranged
from 13 to 98 fmoles/mg in uterine specimens. In parallel
with peroxidase activity, Pg/R content was greatest in uterus
during oestrus, and relatively low in the uterus from a
lactating animal.
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Figure 13.
Concentrations of peroxidase, E/R and Pg/R in a range
ot healthy rat tissues.
tach block represents the mean of duplicate estimations
on a single tissue extract.
hatched blocks indicate that the particular protein
was undetectable.
n/a indicates that no result is available.
Roman numerals indicate the stage in the oestrus cycle
of the rat under study.
1 = proestrus ,• II=oestrus; III =met oestrus ,■ IV=dioestrus
V= intermediate between IV & I.
95
III. COMPARISON 0? PEROXIDASE, S/R AND Pg/R AS MARKERS
FOR HORMONE - DEPENDENCE III RAT MAMMARY TUMOUR
MODELS
A study was mads of levels of the three postulated
markers for oestrogen-dependence (S/R, Pg/R and peroxidase)
in rat mammary tumours which serve as models for hormone-
dependent and -independent growth. In total, 44 tumours
were examined; of these, 24 were DMBA-induced tumours
(models for hormone-dependent growth) and 20 were trans-
plantahle tumours of TG-3 and TG5 lines (models for hormone-
independent growth). The tumours were harvested from the
host animals, extracted and assayed for peroxidase, E/R
and Pg/R as described under the appropriate "Methods".
The Wilcoxon Rank Sum Test was used to analyse the differences
between levels in hormone-dependent and -independent tumours
for each "marker" protein.
RESULTS
The peroxidase content of each of the 24 "hormone-
dependent" and each of the 20 "hormone-independent" tumours
is shown in Figure 14. Peroxidase was undetectable in
6 of the "hormone-independent" group but in only 2 of the
"hormone-dependent" group. The median level in the former
group was only 0.48 u/g wet weight, but was 2.8 u/g wet
weight in the latter. Overall, there was a significant
difference between the levels in the two groups (p <0.001,
Wilcoxon Rank Sum Test). Nevertheless, there was a con¬
siderable overlap between the ranges of peroxidase activities
in the hormone-dependent and -independent groups.
Figures 15 and 16 show the levels of E/R and Pg/R
in a sample of 12 tumours from each of the two groups.
For E/R, the median value in the hormone—dependent tumours
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was 4-5 fmoles/mg wet weight, and in the hormone-independent
group, only 0.3 fmoles/mg wet weight. There was no overlap
whatsoever "between the ranges of S/H level3 in the two
group3.
In the case of Pg/R, the median value in the hormone-
dependent group was 24 fmoles/mg wet weight, and in the
hormone-independent group, less than 0.1 fmoles/mg wet weight.
Again, there was no overlap "between the ranges of levels in
the two groups, with the exception of a single IHBA—induced
tumour in which Pg/R was undetectable.
»
It should be noted that although the hormone-
independent, transplantable tumours have been considered
as one group, within this group, the TG-3 line consistently
yielded higher levels of each marker than did the TG—5
group.
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Figure 14.
Endogenous peroxidase content in rat mammary tumours
which serve as models for hormone-dependent and -independent
growth, bach symbol represents one tumour.
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Figure "l 5 ■
E/R content in rat mammary tumours which serve as models
for normone-dependent and -independent growth.
Each symbol represents one tumour.
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Figure 16.
Pg/R content in rat mammary tumours which serve as models
for hormone-dependent and -independent growth.
Each symbol represents one tumour.
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IV. THE RELATIONSHIP BETWEEN PEROXIDASE ACTIVITY AND B/R
STATUS IN HUMAN MAMMARY TUMOURS
A pilot study was undertaken in an attempt to
identify any relationship between levels of the postulated
marker for hormone-dependence, endogenous peroxidase, and
the established marker, E/R, in human mammary tumours.
In total, 17 tumours were studied. These had been obtained
at operation up to 2 years previously, and had been stored
in liquid nitrogen until the time of assay. Tumour extracts
were prepared and assayed for peroxidase and for S/R as
outlined in the "Methods" section. Information regarding
response to endocrine therapies was available in 3 of the
17 cases.
RESULTS
Of the 17 tumours examined, 6 (357°) contained less
than 0.25 fmoles/mg wet weight of E/R and were designated
E/R-"poor". Peroxidase was undetectable in 4 of the 11
E/R-"rich" tumours, and in 2 of the 6 S/R-"poor" tumours.
The levels of E/R and peroxidase in each of the 17 tumours
are presented in graphical form in figure 17. There is,
clearly, no correlation between the presence or absence of
the two proteins, nor between their absolute levels.
Of the three patients who have subsequently received
endocrine therapies, 2 responded and one failed to respond.
The tumours of the 2 who responded to therapy were positive
for both E/R and peroxidase. The tumour of the patient
who failed to respond was E./R-poor, but contained one of
the highest levels of peroxidase (6.8 u/g wet weight).
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E/R CONCENTRATION AND PEROXIDASE ACTIVITY IN 17
HUMAN MAMMARY CARCINOMAS
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Figure 17.
The relationship between peroxidase activity and E/R
content in 17 human breast cancers.
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A COMPARISON 3BTWB5U THE PEROXIDES ACTIVITY OF
RAT MAMMARY TUMOURS A3 A55533SD 3IOCH3T-TICALL7
AND BY A SIHPIR HI5T0CHBHICA1 T3CEHTIQU5
Host published studies concerning peroxidase as a
marker for oestrogen—dependence have employed a biochemical
assay system similar to the guaiacol method described in
the present work. Histochemical techniques for the detection
of peroxidase are also available, and it has been suggested
that such techniques might provide the basis for a simple
determinant of hormone-dependence, visible at the light
microscope level (DeSombre et al., 1975). In the present
study, the peroxidase activity of rat mammary tumours of
varying hormone-dependency was assessed by means of a very
simple histochemical staining technique. It was felt that
if the results obtained with this technique correlated with
^hose ox tne more complex guaiacol assay, tnen xt mignx
prove to be of practical use as a test of hormone-dependence.
In total, 42 rat mammary tumours were studied. Of
these, 26 were DKBA-induced tumours (largely hormone-dependent)
and 16 were transplantable tumours of TG3 or TG5 lines
(hormone-independent). The tumours were harvested from the
host animals, a portion of each was frozen and processed
histochemically (Method 6) and a further portion was
homogenised and assayed biochemically (Method 5) for
peroxidase activity.
R3SUITS
The peroxidase content of each hormone-dependent
tumour and of each hormone-independent tumour, as assessed
by the biochemical assay, is shown in Figure 13. The
median value for the hormone-dependent tumours wa.s 3.75 G/g,
and for the hormone-independent tumours was only 0.26 U/g.
The difference between the two groups was significant
(V/ilcoxon Rank Sum Test, p 0.01).
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The score allocated to each hormone-dependent
tumour and to each hormone-independent tumour on the basis
of histochemical staining for peroxidase is shown in
Table 6. No peroxidase staining was visible in 12 of 26
hormone-dependent tumours, but staining was visible in all
but one of the hormone-independent group. This difference
is significant (X^ = 5.63; p<0.05).
Overall, 13 of the 42 tumours exhibited no peroxidase
staining, and the remaining 29 were judged histologically
positive for peroxidase. The results of biochemical assay
»
for peroxidase for each of the histologically negative
and for each of the histologically positive tumours are
shown in Figure 19- Paradoxically, the median biochemical
assay result for the histologically negative tumours was
5 U/g, whereas that for the histologically positive tumours
was only 0.55 U/g. This difference is significant
(Wilcoxon Rank Sum Test p 0.01).
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Figure 18.
Biochemical estimates of peroxidase activity in 2b DMBA-
induced and 16 transplantable rat mammary tumours.
Each symbol represents the value tor a single tumour.
Bars indicate the median values.
p< 0.01. C Wilcoxon Rank Bum Test. )
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Table 6 .
Histochemical scores of peroxidase activity in 26 hormone-
dependent and 16 hormone-independent rat mammary tumours.
SCORE HORMONE-DEPENDENT HORMONE-INDEPENDENT
0
1
«
2
12
1 1
3
1
14
1
TOTAL 26 16
7
X =5.63; p<-0.05 for the difference between the number with
absent peroxidase in thetwo groups.
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Figure 'I 9 ■
Biochemical estimates of peroxidase activity in 13
tumours designated histochemically peroxidase-negative
and 29 tumours designated histochemically peroxidase-
positive.
Each symbol represents the value for a single tumour.
Bars indicate the median values,
p.<0.01. (Wilcoxon Rank Sum Test).
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VI. PRELIMINARY INVESTIGATIONS INTO THE SITES AND
MAGNITUDE OF LOSSES OP E/R ACTIVITY DURING
H13T0CHEMI GAL PROCESSING
Because the E/R protein is known to be water-
soluble and thermolabile, it was felt that the "rigours"
of histochemical processing might result in loss of E/R
activity. In particular, cellular disruption during the
cutting of frozen sections and exposure to aqueous pro¬
cessing media might permit the leaching-out of the soluble
E/R from the tissue into the media; also, exposure of the
fragile E/R molecule to conventional histological fixatives
might denature the protein, resulting in loss of activity.
Preliminary experiments were undertaken to quantitate the
effects of these stages of histochemical techniques on
E/R activity. Such activity was assessed by a biochemical
DOC assay on tissue exposed to each histochemical step.
A. -Frozen Section Cutting
An E/R-rich tissue (rat uterus) was removed from
the host animal and a 20 mg portion homogenised and assayed
for E/R by the standard DCC method. (In view of the small
volume of cytosol produced, only three concentrations of
°S2 were employed on this occasion.) A second 20 mg portion
of the uterus was divided into 4 pn frozen sections which
were collected in a cold "Luckham" tube. The sections
were homogenised and assayed for E/R in the same way as the
"intact" portion.
RESULTS
Scatchard plots of the data from E/R assays on the
"intact" and "sectioned" portions of uterus are reproduced
in Figure 20. The concentration of E/R (Pq) in the "intact"
108
and "sectioned" portions of uterus are reproduced in
figure 20. The concentration of S/R (Pq) in the "intact"
portion was 6.69 fmoles/mg wet weight compared with only
2.45 fmoles/mg in the "sectioned" portion.
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Figure 20.
Scatchard plots of E/R assay data on 20 mg. portions
of rat uterus,
o = Intact portion.
• = Portion cut into 4jjm. frozen sections.
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B. Exposure To Aqueous Processing Media
A portion of an E/R-rich tissue (DMBA-induced, rat
mammary tumour) weighing approximately 250 mg was divided
into 4 Aim cryostat sections which were collected in a cold
"Luekham" tube. Tris buffer (2 ml) was then added to the
tube and the contents mixed gently to simulate the exposure
of frozen-sections to aqueous media during histochemical
processing. The sections and buffer were then separated by
centrifuging at 1500 rpm for 10 min. The buffer was removed
with a Pasteur pipette and assayed for E/R by the standard
»
DOC method. A cytosol was prepared from the sections and
also assayed for E/R. The experiment was repeated using
14 ;um rather than 4 jum sections.
RESULTS
Scatchard plots of the data from E/R assays on the
4 jum and 14 Aim frozen sections and from their respective
"processing media" are reproduced in figure 21 . In the case
of 4 jmn sections, four times as much E/R was detectable in
the "processing medium" as in the sections. In the case of
14 jum sections, there was three times as much E/R activity
in the medium as in the sections. In other words, as much
as 66 - 75/> of the total S/R activity in 14 jum or 4 jum
sections seemed to "leach-out" into aqueous media.
111
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Figure 21■
Scatchard plots of E/R assay data on "processing media"
and frozen sections of DMBA-induced rat mammary tumour,
o = Processing medium from 4pm. sections.
■ = Cytosol from 4pm. sections.
& = Processing medium from 14pm. sections.
A = Cytosol from 14pm. sections.
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C. Acetone-Fixation
fixation of frozen sections in acetone prior to
incubation with labelled steroid is a component of at least
one reported technique of E/R histochemistry (Walker et al.,
1960). Preliminary experiments were undertaken to quantitate
the effect of such a fixation step on the E/R activity
present.
a) B/R in the cytosols prepared from acetone-fixed
tissues.
*
•This experiment was performed in triplicate. On
each occasion, rat uteri, weighing approximately 500 mg in
total, were harvested from the host animals. Each uterus
was bisected and one horn allocated to "control-" and the
ether to "acetone-"treatments. The uterine horns were
snipped into small fragments and those allocated to acetone-
Q
treatment were immersed in acetone at 4 0 for 4 min. The
"control" fragments were immersed in Tris buffer at 4°0
for 4 min. Both sets of uterine fragments were then rinsed
in several changes of Tris buffer. After rinsing, cytosols
were prepared from each set of fragments and assayed for
S/R by the standard DOC method.
RESULTS
Scatchard plots of the data from B/R assays on
cytosols from each of the three acetone-treated tissues
and each of the three control tissues are reproduced in
Figure 22. In all three instances, the S/R activity
detectable in acetone-treated tissue was considerably less
than in the control tissue.
b) S/R in the insoluble, tissue reliefs prepared
from acetone-fixed tissues.
As in experiment a), rat uterine horns were allocated
11 3
SCATCHARD PLOTS OF E/R ASSAY ON 3 RAT UTERI TO SHOW EFFECT OF
ACETONE FIXATION
bound
free
uterine horns
unfixed
total mass bound
Figure 22,
Scatchard plots of E/R assay data from cytosols prepared
from rat uterine horns, fixed in acetone or unfixed.
The plots represented bythe same symbol represent portions
of the same uterus.
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to "acetone" or "control" treatments. The appropriately-
treated, uterine fragments were again washed, homogenised
and centrifuged and the resulting cytosols were assayed
for E/R activity. In addition, the centrifugation pellets
were resuspended in Tris buffer (equivalent to 300 mg of
original tissue weight per ml) and 200 ul aliquots were
subjected to E/R assay by the solid-phase system (Method 2).
RESULTS
Inspection of the raw data revealed that there was
no E/R activity present in the pellet preparation from the
control (unfixed) uterine horns. The raw data from the
assays on the "acetone-treated" pellet, "acetone-treated"
cytosol ana "control" cytosol revealed E/R activity in all
3 samples. Scatchard plots were drawn and are reproduced
in figure 23. E/R activity was demonstrable in both pellet
and cytosol after acetone-treatment, but both concentration
(P^), and dissociation constant (2^), were markedly diminished.
The total S/k concentration (pellet plu3 cytosol) detectable
in the acetone-treated tissue was less than half of that
detectable in the cytosol from the untreated tissue.
115
Figure 23.
Scatchard plots of E/R assay data on preparations from rat
uteri, fixed in acetone or unfixed.
o = Cytosol assay on unfixed tissue.
x = Cytosol assay on acetone-fixed tissue.
• = Pellet assay on ace tone-fixed tissue.
(No E/R activity was detectable in pellet assay on
unfixed tissue.)
Results of cytosol and pellet assays are not directly
comparable as reagent concentrations were not
identical.
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D. Bthanol/Acetone "Post-Fixation" .
Another approach to the immobilisation of E/R in
tissue sections is that described by Pertschuk et al. (1979)•
Unfixed, frozen sections are incubated with fluorescein-
labelled oestradiol, rinsed briefly, then fixed for 10 min
in a mixture of equal volumes of ethanol and acetone.
The sections are then extensively washed and mounted for
fluorescence microscopy. An experiment was undertaken
to investigate the effect of a fixation procedure of this> A.
kind on S/R activity. Such activity was assessed by
—g
determination of the saturable binding of L HJ 3p under
conditions similar to those previously used in this depart¬
ment to study nuclear translocation of S/R.
An E/R-rieh tissue (DMBA-induced, rat, mammary
tumour) was removed from the host animal and cut into slices
1 mm thick. Each slice weighed approximately 50 mg. Two
such slices were placed into each of 8 small, conical^
flasks. To 4 of the flasks was added a solution of [/H] ^p
(equivalent to 40,000 cpm; ) in 2 ml of Tris buffer.
A similar solution, to which had been added 50,000 pg of
was ac^ed "to each of the ether 4 flasks. All the
slices were allowed to incubate for 1 hour at 25°C, with
gentle agitation.
The slices from 2 of the flasks containing ^p
alone and from 2 of those containing 3~ plus °^>2 'were
then briefly rinsed and immersed in ethanol/acetone for
10 min to simulate the histochemical, "post-fixation"
process. All slices were then transferred to clean flasks
and allowed to wash in Tris buffer to remove steroid not
bound to the tissue. The slices from each flask were then
transferred to a counting vial, weighed, digested in 5U
sodium hydroxide, mixed with "aqueous" scintillator fluid
and the uptake of tritium-labelled steroid by each set of
slices was determined.
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RESULTS
The uptake of tritium by slices incubated with
CVJ ^2 plus or minus excess °E2 are presented in Table 7.
In the "unfixed" slices, marked tritium-labelling occurred
in those incubated with CV] E2 alone and such labelling
was considerably diminished in those co-incubated with °^2'
Such binding of labelled E2 which could be blocked by the
presence of excess, unlabelled hormone was taken as indicating
the presence of E/R activity. In the case of slices which
were "post-fixed" in ethanol/acetone, minimal labelling
with [/H~| S2 was detectable. This suggested that any
binding of steroid to tissue which occurred during the
incubation period had been abolished by exposure to the
fixative.
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Table 7.
Tritium-labe11ing of tissue sections with and without
ethanol/acetone post-fixation treatment.
FIXATION INCUBATION MEDIUM
COUNTS BOUND
(cpm/mg.tissue) .
NONE
ft
(3H)E.-, only
(3H)E0 + °En
183
51
ETHANOL,/ACETONE
ft
(3H)E~ only
C3H)E0 + °E0
4
6
Each result represents the mean from 2 similarly-treated flasks of
sections.
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V3CI • IEV3STIGATIOiTS INTO POSSIBLE METHODS OF REDUCING
LOBS 0? E/R ACTIVITY DURING HISTQCHEMIOAL
PROCESSING
A. Ammonium Sulohate Precipitation
The ability of ammonium sulphate solutions to
precipitate serum proteins is well documented (Cohn et al.,
1940), An experiment was undertaken to determine whether
or not ammonium sulphate could be used to precipitate the
E/R protein in tissue sections, thus reducing "leaching-
out" into aqueous media during histochemical processing
while avoiding the inactivation associated with conventional
methods of tissue fixation.
An S/R-rich tissue (DMBA-induced rat mammary tumour)
was divided into 4 x 200 mg portions. Each portion was cut
into 4 cryostat sections and the sections from each
portion were collected in a cold "Luckham" tube. To each
of the 4 tubes was added 2 ml of one of the following
solutions: plain Tris buffer or Tris buffer containing
ammonium sulphate to 25, 50 or 75/ of saturation. The tubes
were gently mixed to simulate the exposure of frozen sections
to processing-media during histochemical techniques. The
"processing-media" and sections were then separated and
each was assayed for E/R activity as described in the pre¬
liminary experiment on pHO.
RESULTS
Scatchard plots of the data from S/R assays on each
of the 4 sets of frozen sections and each of the 4 "processing
media" are shown in Figure 24. The ratio of E/R activity
detectable in the "processing medium" against that detectable
in the frozen sections for each concentration of ammonium
sulphate is shown in Table 8. The proportion of the total
E/R activity which "leached-out" into the medium decreased
120
with increasing concentration ox ammonium sulphate. The
Scatchard plots for 75f» saturated solution suggest, however,
that the total, detectable E/R activity was diminished
by exposure to this concentration of ammonium sulphate.
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EFFECT OF INCREASING CONCENTRATION OF ( NH^lz. SO„. ON "LEACHING-OUT*OF EjR INTO
WASH BUFFER.
No (NH^ )2 S04 25 7. SciU NH4 ) 2 S04
bound
E/R activity in wash
solution
A-AE /R activity in sections
1—"—r
4 5
507. Sat.( NH ^ ) 2 SOA 75 7. Sat.( NHi )2 SO^
bound
4 5
total mass bound ( pg )
1 2 3 4 5 6
total mass bound ( pg )
Figure 24.
Scatchard plots of E/R assay data on "processing media"
and frozen sections of DlvlBA-induced rat mammary tumour.
The media contained various concentrations of ammonium sulphate
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Table 8.
The effect of various concentrations of ammonium sulphate
□n the "leaching-out" of E/R activity from frozen sections
into processing; media.
% saturation
medium
Ratio E/R activity in , .J sections
0 4.6/1
*
25 1 .2/1
50 0.1/1
75 0.05/1
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B, Protamine Sulphate Precipitation
Protamine sulphate, like ammonium sulphate, induces
precipitation of various proteins, including E/R. It was
felt that treatment of frozen sections with protamine
sulphate might provide a means of immobilising E/R without
inactivation. As a preliminary investigation into the
feasibility of such an approach, an attempt was made to
reproduce the results of Chamness et al. (1975) and of
Lippman and Huff (1976) in demonstrating the retention of
E/R activity in protamine-precipitated pellets prepared from
*
an E/R-rich cytosol. A cytosol was prepared from rat
uteri and aliquots were assayed for E/R by the standard
DCC method (Method 1). Further aliquots were subjected to
the "solid-phase" assay technique (Method 2). The experimen
was performed in duplicate.
RESULTS
Scatchard plots of the data from the E/R assays
on the cytosol and protamine-precipitate from each of two
rat uteri are reproduced in Figure 25. The values of P0
and from each assay are presented in Table 9.
Similar values of P (concentration of E/R) for
each uterine specimen were derived from the cytosol and
solid-phase assays. The (reflecting strength of E/R
binding) was, in contrast, apparently impaired in the
solid-phase preparations of both specimens.
LoVvere fete s©tAd - pWse pellets coere prepared in a -final
nor\cejnJcra3:iov\ d£ o.RS> wg protaiAAjne Sulphate.
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bound ( pgs)
Figure 25.
Scatchard plots of E/R assay data on preparations from
rat uteri.
o = Cytosol assay. Specimen 1.
A = Cytosol assay
_ Specimen 2.
a = Protamine pellet assay. Specimen 1.
= Protamine pellet assay. Specxnien 2.
(Note that pellet assays were undertaken on tissue aliquotq
of double the mass of the aliquots used for cytosol assays
and, thus, Scatchards are not directly comparable.
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Table 9.
Characteristics of E/R activity detectable in cytosols and
protamine sulphate precipitated pellets from two specimens
of rat uterus.
PREPARATION
o
Q_ Kd
CYTOSOL 1. 15.4 0 . 31 x1 0~1°N.
CYT-OSOL 2. 11.4 0.85x10"10N.
PELLET 1. 15.5
- 1 0
5.2x10 M.
PELLET 2. 10.1
- 1 0
1.4x10 M.
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rai • EVALUATION OF HISTOCHEHIGAL TECHNIQUES USING
GLASS - MOUNTED FROZEN SECTIONS
In the experiments described in the preceeding
sections the E/R activity remaining in tissues after
processes analogous to those used in histochemistry has
been quantitated by means of conventional E/R assays. In
the following experiments an attempt has been made to
evaluate the effects of similar processes on the E/R which
can be detected in glass-mounted frozen sections, a situation
which more closely resembles the proposed histochemical
methodology.
A. E/R Activity In Unfixed. Glass-Mounted .Frozen Sections
This experiment was performed on 5 occasions. In
each case, portions of the tissue under study were cut into
cryostat sections, mounted on coverslips, incubated with
[/'if] E2 with or without °E2» washed for varying periods
of time in buffer and tritium-labelling determined as
described in "Method 3".
RESULTS
The results of these studies in E/R-rich tissues
(rat uterus and DKBA-induced mammary tumours) and in an
E/R-negative tissue (rat cerebral cortex) are presented
in Table 10. Both 4 Aim and 14 jura sections, and both
minimal and extensive washing regimes, were studied. After
minimal washing, there was enormous tritium-labelling of the
sections which was not diminished by co-incubation with
°E2. In the E/R-rich tissues subjected to a 1 hour washing
process, differential labelling between the sections
incubated with E2 alone and those co-incubated with °E2
occurred, this is indicative of E/R activity. In the case
127
of the E/R-negative tissue studied, similar differential
labelling did not occur, although high "non-specific"
"binding was present.
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Table 10.
Trit i urn-labe 11 in g of unfixed,glass-mounted,frozen sections
3
after incubation with ( H)E7 + 0p-
r b2''
TISSUE
Thickness
(jjm. )
Wash time.
(hr. )
cpm. ()E£
3
cpm. C H)E2
Rat uterus 4 0 115450 152100
□MBA-tumour 1 . 4 1 506 120
2 . 4 1 2223 1505
3 . 14 1 2534 1948
rat cerebrum 14 1 2125 4442
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B- S/R Activity In Acetone-Fixed, Glass-Mounted.
Frozen Sections
Five tissues were examined for their capacity to
bind oestrogen "specifically", after acetone fixation:
one human uterus, two DMBA-induced, rat, mammary tumours
(S/R-rich tissues), and two samples of rat duodenum
(E/R-negative tissue). In each experiment, approximately
200 mg of tissue was cut into frozen sections, mounted onto
coverslips and then immersed in acetone, at room temperature,
»
for 4 minutes. The acetone was allowed to evaporate before
"flooding" the sections with steroid solutions and pro¬
cessing by the method described for the assay of S/R
activity in glass-mounted, frozen sections (method 3).
Post-incubation washing was in three changes of PBS for a
total of 1 hour.
RESULTS
The tritium-labelling of the fixed sections from
each tissue after incubation with C Hj[ E^, with or without
excess °^2> s^-own in Table 11. In each of the "E/R-rich"
tissues there was differential labelling between the sections
incubated with alone and those co-incubated with
excess °^2' indicative of E/R activity. Such differential
labelling was not apparent in the case of the E/R-negative
tissues.
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Table 11.
Tritium-labe11ing of acetone-fixed, glass-mounted, frozen
3 0 ~~
sections after incubation with (H)E^ E^_i_
TISSUE cpm. 3(HiEq ,^ 2 only. 3(HJEq+°E0.cpm. 2 2
Human uterus 1699 241
DMBA-tumour 1. 1 578 656
DMBA-fumour 2. 1048 573
Rat duodenum 1 . 238 244
Rat duodenum 2. 207 185
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C. 3/R Activity In Ammonium Sulrhate-Treated, Glass-
Mounted, Frozen Sections
This experiment was performed on two occasions
using 14 sections of a DMEA-induced, rat, mammary tumour.
On each occasion, one set of frozen sections was subjected
to the "glass-mounted E/R assay" (Method 3), without any
form of fixation and using Tris buffer as the post-incubation,
washing medium. A second set of frozen sections from each
tumour was assayed similarly except that the incubation
and washing media contained ammonium sulphate at 505° of
saturation.
T?"VCJ7TT rp qItibO U Jj-L O
The tritium-labelling of sections incubated with
Eg, with and without excess °S9, in the presence or
absence of ammonium sulphate, is shown in Table 12.
E/R activity, indicated by differential labelling between
sections incubated with [/^Q Eg alone and these co—incubated
with excess °3g, was not convincinglj'- demonstrated in tissues
processed in the presence or absence of ammonium sulphate
in these experiments. The presence of ammonium sulphate
in the processing media seemed to greatly increase "non¬
specific" binding of tritium-labelled steroid to the tissue
sections.
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Table 12.
Tritium-labelling of glass-mounted, frozen sections with and
without ammonium sulphate in the processing media.
EXPERIMENT MEDIA
3
cpm. ( H]only.
, 3U 4 r- 0,-
cpm. (. HJE2+ E-2'
1
no
(NH„ISO,
481 731
1
»
with
(NH4)S04
1 1359 10523
2
no
CNH4)S04
479 305
2
with
(NH4)SD4
81 98 1 0505
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5. 3/R Activity In Protamine Sulphate-Treated, G-lass-
Hounted, Frozen Sections
Frozen sections (14 Aim) of DMBA-induced, rat,
mammary tumour were cut and mounted on glass coverslips.
One set of such sections was assayed, unfixed, for E/R
activity by Method 3- A second set was "flooded" with a
solution of protamine sulphate (1.5 mg/ml) for 5 minutes,
then rinsed in PBS prior to incubation with steroid
solutions and subsequent processing as described in
♦
Method 3.
RESULTS
The tritium-uptake of sections processed with and
without protamine-treatment are shown in Table 13• The
frozen sections processed in the absence of protamine
sulphate-treatment did not show any evidence of S/R activity
as indicated by decreased uptake of tritium in the presence
of excess °Eg. protamine-treated sections, however,
did show differential tritium-labelling between those
incubated with PhD Eg alone and those co-incubated with
excess °Ep. However, almost 50*?° of the total pfQ Eg
binding appeared to be "non-specific", i.e. was not blocked
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Table 13.
Tritium-labelling of glass-mounted, frozen sections with and
without protamine sulphate treatment.
MEDIUM
3
cpm. ( H)E2 only. cpm. C ^H 1 E^ + ^2 "
No protamine. 885 1023
+ protamine. 2071 1 070
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IX. CHARACTERISATION OP THE CONJUGATES SYNTEESISED FOR
s/r histochemistry
Conjugates of oestradiol, BSA and a visible tracer
(fluorescein or horseradish peroxidase) were synthesised
as described in Methods 7 and S. The following investi¬
gations were made in an attempt to confirm the incorporation
of all three components into the final conjugates.
A. ' Fluorescein Gon,1urates
Perischuk et al. (1980) reported that they were
able to confirm incorporation of oestradiol, BSA and fluore¬
scein into their conjugates by the demonstration of
absorhance peaks at 279, 230 and 495 mp.. respectively.
The absorbance spectra of samples of oestradiol-BSA-fluore—
scein donated by Br. Pertschuk and synthesised by the
present author and also of the BSA-fluorescein "control"
conjugate synthesised by this author were constructed
using a Unicam SP800 U.V. scanning spectrophotometer.
RESULTS
The absorbance spectra of the three conjugates,
together with the spectrum of a reference sample of albumin
solution, are reproduced in Figure 26. Consideration of
the fluorescein peaks at 495 mu. indicates that incorporation
of fluorescein into the author's conjugate was similar to
that found in Dr. Pertschuk's. It proved impossible, in
practice, to distinguish between the peaks for oestradiol
and BSA at 279 and 230 mu. respectively. In this region of
the absorbance spectra, therefore, no distinct difference
could be discerned between the absorbance patterns of
conjugates containing both oestradiol and BSA and that
136
containing B3A but no oestradiol. These spectra do, however,
indicate that the "control" conjugate synthesised by the
author is less heavily labelled with fluorescein per nig
of conjugate than either of the oestradiol-containing
conjugates.
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absorbance
1
»
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oestradiol
BSA
fluorescein quoted
peaks for
components
wavelength (millimicrons )
Figure 26.
Absorption spectra of fluoresceinated conjugates.
A = Albumin reference curve.
B = Oestradio1-BSA-Fluorescein synthesised by the author.
(0.1 mg/ml.)
C = Similar conjugate synthesised by Ur. L.Pertschuk.
(0.05 mg/ml.)
0 = BSA-Fluorescein. (0.1 mg/ml.)
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B. Peroxidase Conjugates
The second class of conjugates studied comprised
oestradiol, B3A and peroxidase and were based on that
described by Walker et al. (1980). Por the synthesis of
these conjugates a commercial preparation of BSA-oestradiol
(from Sterloids) was purchased and the final conjugation
step, the linkage of HHP, was undertaken by the author,
as described in Method 8. An aliquot of the final conjugate
solution (Method 8a) was assayed for peroxidase activity
by the routine guaiacol method (Method 5) in order to confirm
the ihcorporation of active peroxidase into the final material.
RESULTS
The peroxidase activity of the final conjugate was
found to be 40 units/ml, indicating that the final conjugate
was rich in active peroxidase.
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S/R - BINDING AFFINITIES 0? 03STRADI0L CONJUGATES
The following experiments were undertaken in an
attempt to confirm that the oestradiol conjugates, which
had "been synthesised for use in E/R histochemistry, were,
in fact, able to bind to E/R, at least in its cytosolic
form. In addition, the relative binding affinities of
these conjugates for the B/R (relative to that of oestradiol-
17P) were determined to aid in the selection of appropriate
conjugate concentrations for histochemical techniques.
The ability of the compound under test to displace [/'eQ
from cytosol binding sites was regarded as evidence of
B/R binding. The following compounds were subjected to
competitive binding studies:
1. Oestradiol 1 7fh
2. Oestradiol - BSA - fluorescein donated by
Dr. L. Pertschuk.
3. Oestradiol - BSA - fluorescein synthesised
by the author.
4. B3A - fluorescein "control" conjugate.
3. 6 keto - oestradiol 17J3 (precursor of the
peroxidase conjugate).
6. Oestradiol - BSA (intermediate in preparation
of peroxidase conjugate).
7. Cestradiol - BSA - peroxidase.
8. CI628 (anti-oestrogen used as an E/R "blocker").
For these studies, aliquots (100 pi) of an E/R-rich
cytosol, prepared from pooled rat uteri, were incubated
with a fixed mass (10 pg) of B2 and varying masses of
the test compound, in a manner similar to that described
for the routine assay of E/R activity.
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RESULTS
The increasing displacement of [/'eQ E? from cytosolic
receptor sites by increasing concentrations of the various
test compounds is shown in Figure 27 (fluorescein conjugates
and CI623) and Figure 23 (peroxidase conjugate and pre¬
cursors). A curve for oestradiol-17jB is shown in each case
for comparison. With the exception of the "control" con¬
jugate, BSA - fluorescein, all the compounds tested were
able to displace ^2 -rom binding sites. The
binding affinities of the compounds studied varied consider¬
ably as indicated by the variations in molar concentration
needed to achieve 50fo displacement of E^. The ratio
of the concentration needed for oestradiol-1 Tp to that
needed for each test compound, (i.e. the relative binding
affinity) is presented in Table 14. The affinities are
expressed in terms of the binding potency of 1 mole of each
conjugate (containing between 5 and 33 moles of oestradiol)
or steroid relative to a value of 1 for oestradiol-1 TjB.
Under the conditions of this study, 01628 was found
to have the highest affinity for E/R binding sites, being
4 times as potent as oestradiol-1 lf>. The precursor of the
peroxidase conjugate, 6 keto-oestradiol 17fh had a relative
potency of only 0.13 and the conjugates based on it proved
to be less potent than the fluorescein conjugates.
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ratio of competitor to tritiated E2
(molar basis)
AFFINITIES OF STEROIDS AND CONJUGATES FOR OESTROGEN RECEPTOR
radio
ligand
'counts*
bound
Oestradiol 17/3
Oestradiol-BSA-Fluorescein -suppliedbyL.Pertschuk
synthesised in our lab.
BSA - Fluorescein
CI 628
Figure 27.
3Curves illustrating the displacement of (H)Oestradiol
from cytosol receptor sites by fluoresceinated conjugates
ana related compounds.
142:
o oestradiol 17/3
x 6keto oestradiol 17/3
Figure 28.
3
Curves illustrating the displacement of ( HlOestradiol
from receptor sites by peroxidase conjugate and related
compounds.
Figures on the "Y" axis indicate "radio-ligand bound" as a
% of the total bound in the absence of competitor.
Figures on the "X" axis indicate the ratio of competitor
3
to ( FDE2 on a molar basis.
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Table 14.
Relative binding activities of conjugates, conjugate
precursors and control solutions as used for E/R histochemistry.
Binding activities relate to the molar concentrations of each
3
compound which causes 50% inhibition of ( HIE,, binding, on a
basis of Oestradiol 17B = 1 .
COMPOUND. Relative activity.
Oestradiol 17[3 1\
Oestradiol-BSA-Fluorescein (Pertschuk). 0.8
" (Present author ) . 0. 05
BSA-Fluorescein. 0. 00
6-keto-oestradiol 17|3. 0.13I
B-keto-oestradiol-BSA. 0. 09
B-keto-oestradiol-BSA-peroxidase. 0.02
CI 628 4.4
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XI. EVALUATION 0? 0E5TRADI0L CONJUGATES FOR THE
LOCALISATION OF E/R IN FROZEN SECTIONS
A. Fluorescein Tracer
The histochemical technique of Pertschuk et al.
(1979), described in Method 9, was carried out on a range
of human and rat tissues u3ing a specimen of the oestradiol-
BSA-fluorescein conjugate donated by Dr. Pertschuk and a
specimen of the similar conjugate synthesised by this
author (Method 7). The tissues examined included bio¬
chemically E/R-rich tissues (DMBA—induced rat mammary
tumours and rat uteri), a biochemically E/R-negative tissue
(rat duodenum), a tissue reported by Dr. Pertschuk as
strongly histochemically E/R-positive (rat skin) and also
frozen sections and cytological smears of human mammary
cancers.
RESULTS
As a baseline for the interpretation of sections
incubated with fluorescein conjugates, fresh sections of
rat uterus and duodenum were mounted and examined under
the fluorescence microscope and auto-fluorescence was
found to be minimal.
Examination of sections of rat uterus incubated with
the oestradiol-BSA-fluorescein conjugates revealed widespread
fluorescence. In particular, the nuclei of certain cells
of the myometrial layer were brightly fluorescent, as was the
cytoplasm of the endometrial cells. In control sections
incubated with the conjugate of B3A and fluorescein alone,
the distribution of fluorescence was similar but the overall
intensity was less. In those control sections co-incubated
with an excess of competitor (diethylstilboestrol, CI 628
or tamoxifen) no diminution of fluorescence was observed.
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Even when the concentration of competitor was increased to
the point of saturation, the intensity of fluorescence
appeared to he unimpaired, although very high competitor-
concentrations appeared to have a non-specific "tissue-
disruptive" effect.
Sections of rat duodenum, biochemically an E/R-
negative tissue, were incubated with the sane three solutions.
In those incubated with oestradiol-BSA-fluorescein, a wide¬
spread fluorescence, particularly intense in the endothelial
layer, was seen. The distrubution of fluorescence in a
transverse section of duodenum was remarkably similar to
that seen in a similar section of uterus. Again, sections
of duodenum incubated with the conjugate of B3A and
fluorescein alone showed a similar, but less intense
fluorescence and those co-incubated with the competitors
showed tissue damage but no diminution of fluorescence.
In rat and human mammary tumours, widespread
fluorescence was seen in all specimens examined. Again,
the appearances of the "control" sections were of a
similarly distributed but less intense fluorescence in the
case of BSA-fluorescein-incubated sections, and of tissue
disruption but unimpaired fluorescence in the case of
sections co-incubated with competitors. In the specimen of
rat skin, certain cells at the bases of hair follicles
exhibited very bright fluorescence but, as with the other
tissues studied, this fluorescence was not diminished in
sections co-incubated with excess competitor.
In a further experiment, sections of rat uterus
were washed in "normal swine serum" prior to incubation
with the conjugates in an attempt to block non-specific
protein binding sites. However, this treatment did not
result in a reduction in the distribution of tissue
fluorescence.
It was noted that the appearances obtained after
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incubation with Dr. Pertschuk's conjugate were essentially
the same as those obtained after incubation with the
conjugate synthesised by the author.
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E. Peroxidase Tracer
Human and rat tissues were studied by the method of
v/alker et al. (1930) using a conjugate of oestradiol, B3A
and HHP (Method 10). Conjugates prepared by the method of
Hakane and Kawaoi (8A) and by the method of Avrameas and
Ternynck (<3B) were used. The tissues examined included
biochemically E/R-positive tissues (human and rat reproductive
tract and human tumours of mammary origin) and biochemically
E/R-negative tissues (rat duodenum, skin and muscle and
human mammary tumours). Prior to incubation with HRP-
labelled conjugates, comparable sections of all the tissues
under study were stained for endogenous peroxidase as in
Method 6.
RESULTS
a) Endogenous, Peroxidase
Endogenous peroxidase staining was found to be
abundant in the sections of human uterus and rat duodenum
examined. These tissues were, therefore, considered unsuit¬
able for study by the peroxidase-tracer technique as it would
have been impossible to distinguish between endogenous
and HHP staining. In all other tissues examined, endogenous
peroxidase staining was minimal or absent (as indicated in
the examples, Figures 29 - 32) and did not interfere with
the interpretation of sections incubated with peroxidase-
labelled steroid.
b) Concentration Of Conjugate Used
The concentration of each conjugate to be used for
histochemical studies was determined by preliminary staining
of sections of rat uterus with various dilutions and
selecting the one which gave rise to easily visible, but
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localised, brown staining. Conjugates GPt (prepared by
Method 8a) and G-P4 (prepared by Method 8b) which had not
been purified (and hence diluted) by Sephadex chromatography
were used at dilutions of 1/8 to 1/20. Conjugate GP3
(prepared by Method 8b) had been diluted during Sephadex
chromatography and it was found necessary to use it without
further dilution. Conjugate GP2 (Method 8b), which was
also purified on Sephadex, was found to be too dilute to
produce any detectable staining.
c) Appearances After Histochemical Processing
The microscopic appearances after histochemical
processing of 25 tissues, in which interpretation was not
complicated by the presence of endogenous peroxidase
staining, are summarised in Table 15. The E/R content of
each tissue, as measured by DCC assay, is shown for comparison
with the histochemical appearances. In all the tissues with
high E/R levels, as assessed biochemically, cellular uptake
of conjugate was demonstrable. However, when the same tissue
was examined on several occasions (e.g. rat uterus, assays
5-7 and breast cancer metastasis, assays 21 - 2A)
reproducibility seemed to be very poor. Cellular uptake
of conjugate was also demonstrable in many of the biochem¬
ically S/R-negative tissues studied, for example, the
squamous epithelium of rat ear, rat cheek muscle and some
human tumours (assays 18 and 19).
Attempts were made to demonstrate blocking of
cellular uptake of conjugate in comparable frozen sections
by co-incubation with excess of a suitable competitor.
Competitors used were diethylstilboestrol (EES), tamoxifen
and CI 628 as indicated in the table. In order to obtain
blocking in any instances, it was found necessary to use
the competitors in saturated solution. CI 628 was found to
be unsatisfactory as its yellow colour and tissue-disruptive
effect made interpretation of frozen sections which had been
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exposed to it very difficult (assaj^s 10 and 11). Convincing
blocking was achieved with OSS in assays 1, 4 and 21 and
with tamoxifen in assay 12. Photomicrographs illustrating
this blocking in these 4 tissues are reproduced in
Figures 29 - 32. In other tissues which exhibited cellular
uptake of conjugate, blocking could not be achieved; this
was true of both biochemically E/R-positive tissues
(assays 2, 3, 5, 15) and biochemically E/R-negative tissues
(assays 8, 9, 18, 19). In other cases (assays 6, 7, 10,
11, 14, 24) the appearances of "co-incubated" frozen sections
were regarded as equivocal because of tissue-disruption or
precipitation of competitor or DAJB over the section.
Overall, of the 25 tissues presented here, 19 had
appreciable E/R activity as assessed by DCC assay. Of these
19, only the 4 illustrated in Figures 29 - 32 exhibited
cellular uptake of conjugate which was diminished by co-
incubation with competitor; thus, only in these 4 might
it be claimed that S/R had been demonstrated. Of the
6 E/R-negative or very low positive (DCC basis) tissues,
only 2 (assays 13 and 25) exhibited minimal uptake of
conjugate. The remaining 4 (assays 8, 9, 18, 19) did
exhibit uptake of conjugate but blocking was not demonstrable.
In only 6 of the 25 tissues, therefore, was full agreement
with DCC assay obtained.
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TABLE 15.
Summary of results of histochemica1 staining for E/R,
using peroxidase tracer, in 25 tissues with no detectable
endogenous peroxidase staining.
The value for E/R content of each tissue obtained at DCC
assay (Pq) is shown for comparison.
The conjugates used for staining each tissue are listed
according to the following code:
GP1 : conjugate prepared by Method 0a.
GP3 : " " " " 8b.
GP4 : second conjugate prepared by method 8b.
*\ssay No.
TISSUE
DCC po
CONJUGATE
BLOCKER
CELLULARUPTAKEDF CONJUGATE
? 3L0CKING
AGREES aJITHDCC?
1
Immaturer tuterus I
10.24
GP41/8
DES
+++vaginal&ectocervica squamousepitheli m.
1
Partia1
+
2
Immaturer tuterus II
13.34
GP41/12 "1/16
DES
+++Alllayers.
No
?
3
Lactatingruterus I
14.9
GP41/8
DES
+++endometrium ++otherlayers.
No
7
4
Lactatingrauterus
I(2nd.assay).
14.9
GP41/16
DES
asbove.
Partia1
Y
5
Lactatingruterus II
11.5
GP41/8
DES
+++alllayers.
No
?
6
Lactatingruterus II(2nd.assay)
11.5
GP41/8
DES
+only.
?
7
7
Lactatingruterus II(3rd.assay.)
11.5
GP41/3
DES
+++alllayers.
?
7
B
Ratear.
0
GP41/8
DES
+++squamousepith.Parti hairfollicles.
cNo
7
9
Ratcheekmuscle.
0
GP41/8
DES
+
No
7
10
Humanbreastcancer. (LD)
3.58
GP11/10
31628
++Cancercells;-stroma &lymphocytes.
?
7
1
Humanbreastcancer (LD)2nd.assay.
II
GP11/20
31628
asbove
7
7
12
Humanbreastcancer (LD)3rd.assay.
II
GP3
Tamox.
asbove
Yes
+
13
Humanbreastcancer (IN)
0
GP3
Tamox.
none
+
14
Humanbreastcancer (3)
5 .0
GP41/12 "1/16
DES
+
?
7
15
Humanbreastcancer (4)
8 .0
GP41/8
DES
+
No
7
Assay
No
TISSUE
□CC po
C0N3UGATE
BLOCKER
CELLULARUPTAKEOF CONJUGATE.
? BLOCKING
AGREESWi DCC?
16
Humanbreastcancer (5)
1 .7
GP41/8
DES
minimal,stroyce1Is.
?
?
17
Humanbreastcancer (6)
4.7
GP41/8
DES
Cells<£stroma(+)
?
?
18
Cystosarcoma.
0
GP41/8
□ES
+
No
"
19
Humanbreastcancer mn
0
GP41/8
DES
+
No
20
1.ovarian2Ufr m humanbreastj-jCancer.
7.35
GP3
omitted
+
(+)
21
r.ovarian2fr m humanbreastcancer.
1.71
GP41/8
DES
+
Partial
+
22
asbove(2ndassay)
GP41/8
DES
none
23
asbove(3rd.ssay)"
GP41/8
DES
none
24
asbove(4th.s a
y)"
GP41/8
DES
+
?
?
25
Benignmammary hyperplasia
0.6
GP41/8
DES
+
?
?
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b.
Figure 29,
Frozen sections of immature rat vagino-cervica1 junction.
(See Table 15, assay 1.)
a) Toluidine blue stain to demonstrate tissue architecture
b) DAB-Fi2D2 stain to demonstrate endogenous peroxidase,
Mayer's haematoxylin counterstain.
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Figure 29 (cont.)
c) After incubation with oestradiol-BSA-peroxidase
conjugate, flayer's haematoxylin counterstain.
d) After co-incubation with oestradiol-BSA-peroxidase
conjugate and competitor (DES), Flayer's haematoxylin
counterstain.
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(Counterstain too pale for
photographic reproducti on .)
b.
Figure 30.
Frozen sections of lactating rat uterus.
(See Table 15, assay 4).
a) Toluidine blue stain to demonstrate tissue architecture
b) OAB-H^O^ stai to demonstrate endogenous peroxidase,
Flayer's haematoxylin counterstain.
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Figure 30 Ccont. )
cj After incubation with oestradiol-BSA-peroxidase conjugate.
Mayer's haematoxylin counterstain.
d) After co-incubation with oestradiol-BSA-peroxidase
conjugate and competitor (DES), Mayer's haematoxylin
counterstain.
Figure 31 .
Frozen sections of human breast cancer cells.
(See table 15, assay 12.)
a) Haematoxylin & Eosin stain to demonstrate tissue
architecture.
b) DAB-h^C^ stain to demonstrate endogenous peroxidase,
Mayer's haematoxylin counterstain.
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Figure 31 (cont. )
c) After incubation with oestradiol-BSA-peroxidase
conjugate. Mayer's haematoxylin counterstain.
d) After co-incubation with oestradiol-BSA-peroxidase
conjugate and competitor (Tamoxifen). Mayer's
haematoxylin counterstain.
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b.
Figure 32.
Frozen sections of ovarian metastasis from human breast
cancer.
(See Table 15, assay 21).
a) Toluidine blue stain to demonstrate tissue architecture.
b) DAB-F^C^ stain to demonstrate endogenous peroxidase,
Mayer's haematoxylin counterstain.
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Figure 32 Ccont.) ,
c) After incubation with oestradiol-BSA-peroxidase
conjugate, Mayer's haematoxylin counterstain.
d) After co-incubation with oestradiol-BSA-peroxidase
conjugate and competitor (DBS), Mayer's haematoxylin
counterstain.
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PART IV
DISCUSSION
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I. ENDOGENOUS PEROXIDASE AS A MARKER FOR HORMONE-DEPENDENCE
A. Establishment Of Assay Techniques
The series of experiments described in "Results I"
was undertaken to determine optimal substrate concentrations
and assay conditions for a spectrophotometric peroxidase
assay. The ranges of substrate concentrations tested were
chosen by consideration of the levels used by other workers
(Maehly and Chance, 1954; Himmelhoch et al., 1969; Putter,
1974; Lyttle and DeSombre, 1977) in similar assay systems.
Graphs relating initial rate of reaction to substrate
concentration were constructed for both guaiacol and hydrogen
peroxide with a view to selecting substrate concentrations
corresponding to maximum initial rates of reaction, i.e.
concentrations adequate to "saturate" amounts of enzyme
likely to be encountered in practice.
A value for Michaelis Constant (K ) with respect tom
guaiacol was readily determined and an assay concentration
equivalent to 9 x Km was selected. In the case of hydrogen
peroxide, however, a distinct "plateau" region on the initial
rate/concentration curve, indicating enzyme-saturation, was
not obtained within the range of concentrations tested.
Nevertheless, a value for Km with respect to hydrogen peroxide
was calculated from the straight-line (Lineweaver-Burke) plot
of the assay data. The chosen assay concentration proved to
be approximately equal to Km, and although far from ideal
in theory, was similar to that used by Lyttle and DeSombre
(1977) in their assay. It is, perhaps, not surprising that
this difficulty in the selection of peroxide concentration
arose as Putter (1974) has stated that the kinetics of the
guaiacol reaction are such that a true value of K withJH
respect to hydrogen peroxide probably cannot be determined.
Further preliminary experiments served to ensure
that the optimal method of estimating "initial" rate of
reaction was chosen, and to demonstrate that the assay
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"precision" (intra-assay variation) was good (approximately
Ho). In addition, the assay was validated by demonstration
of linear relationships between increase in absorbance
measured under the routine conditions and known concentrations
of both horseradish and uterine peroxidases. Finally, the
stability of peroxidase activity in liquid nitrogen storage
was established.
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B. Peroxidase Activity In Normal Rat Tissues
The study described in "Results II" involved the
measurement of peroxidase activity in a orange of normal
rat tissues; namely liver, kidney, prostate, testis, erythro¬
cytes, spleen, mammary gland and uterus during various
reproductive states. Peroxidase activity was detectable in
all the tissues examined except liver and kidney, the highest
values being found in uterus. Several groups of other
workers have presented data on peroxidase activity in normal
rat tissues in the past. In 1934, Bancroft and Elliot used
a rather crude assay technique, without the benefit of
calcium chloride extraction and using pyrogallol as hydrogen
donor. In contrast with the present study, they detected
peroxidase, in small amounts, in liver and kidney, but found
it to be absent from mammary gland. They found the highest
levels in spleen and lung, but did not examine the uterus.
In a later study, Heufeld et al. (1958) examined
a larger range of tissues. In agreement with the present
work, they could not detect peroxidase in liver, found
high levels in the uterus and intermediate levels in spleen
and lung. However, they were able to detect a low activity
in kidney and found the highest levels in small intestine,
which was not examined in the present study. Lyttle and
DeSombre (1977) have also assayed a range of normal rat
tissues. They found the greatest activity in spleen, high
levels in oestrogen-stimulated uterus and also in lung, a
low level in kidney, and, as in the present study, found no
activity in liver.
In general, therefore, the results of this study are
in agreement with those of other groups: endogenous peroxi¬
dase is detectable in a wide range of normal tissues of the
rat, both classical oestrogen-target tissues such as uterus,
and non-target tissues such as spleen. In the target tissues,
uterus and mammary gland, peroxidase levels are higher when
the tissue is under oestrogen-stimulation (during oestrus or
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after administration of exogenous hormone) than in the
unstimulated tissue (during lactation or after castration).
This finding indicates that endogenous peroxidase does seem
to serve as a marker for oestrogen-target cell interaction.
The relative levels of peroxidase found in the various
tissues in this study are similar to those found by the other
groups of investigators. The comparison is summarised in
Figure 33•
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Tissue Present work
Bancroft&Elliot
(1934)
Neufeld et.al.
(1958)
Lyttle &Desombre
(1977)
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Figure 33 ■
Levels of peroxidase detected in a range of normal rat
tissues by various investigators. Because of the differing
assay techniques of the various groups, results have
been expressed as a % of the result obtained for spleen
by each group. Where no value is shown, that tissue was
not examined by that particular group of authors.
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C. The Relationships Between Levels Of Peroxidase,
E/R And Pg/R In Normal Rat Tissues.
In the study described above, E/R and Pg/R levels
were measured, in addition to peroxidase activity, in a range
of normal rat tissues. Like peroxidase, E/R was found to
be very widely distributed, being detectable in all the
tissues examined except erythrocytes. Stumpf and Sar (1976)
have also estimated the E/R content of normal rat tissues,
using an autoradiographic technique. In addition to the
classical oestrogen-target tissues (uterus, vagina, oviduct,
mammary gland, anterior pituitary, hypothalamus) they were
able to detect oestrogen-target cells in testis, prostate,
kidney and liver, all of which were examined, and found to
be B/R-positive, in the present study. Stumpf and Sar
examined an exhaustive range of tissues and, in addition to
those mentioned above, reported oestrogen-binding in thymus,
adrenal, many parts of the male reproductive tract, heart,
diaphragm, salivary glands, arterial walls and central
nervous system.
In the present work, Pg/R was found to be much less
widely distributed, being present only in the classical
target-tissue, uterus, in lung and in kidney. Stumpf and
Sar (1976) studied progestogen-binding by means of auto¬
radiography and reported the finding of target cells in
female reproductive organs and in the pituitary but not in
central nervous tissue nor, to their satisfaction, in liver.
Thus, in general, peroxidase, E/R and, to a lesser
extent, Pg/R are widely distributed in normal rat tissues,
the highest levels of all three proteins being found in the
classical oestrogen-target tissue, the uterus. In target
tissues (uterus and mammary gland), the levels of all three
proteins vary depending on the reproductive status of the
host animal. Detectable E/R levels are highest when circu¬
lating oestrogen is low (e.g. during lactation), but rela¬
tively low during oestrus when high endogenous oestrogen
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levels "block" E/R from binding to radiolabelled-oestrogen.
In contrast, both Pg/R and peroxidase levels are highest
during oestrus and relatively low during lactation, lending
support to the hypothesis that synthesis 0f both these
proteins is dependent on oestrogen - E/R interaction.
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D. Peroxidase. E/R And Pg/R As Markers For Hormone-
Dependence In Rat Mammary Tumour Models.
Following the implication from the study of healthy
rat tissues, that peroxidase does seem to serve as a marker
for oestrogen-dependence, this property was further investi¬
gated in a series of rat mammary tumours which serve as
models for hormone-dependent and -independent growth
(Results III). The tumour models have been validated in a
previous study from this department (Scott et al., 1979).
These workers showed that all of 12 DMBA-induced rat mammary
tumours regressed after oophorectomy, whereas none of 12 TG-3
tumours and none of 6 TG-5 tumours did so. Hawkins et al.
(1978) have presented typical growth curves for each of the
3 types of tumour. In view of these data, DMBA-induced
tumours were accepted as models for hormone—dependent growth
and transplantable tumours of TG-3 and TG-5 lines were accepted
as models for hormone-independent growth for the purposes
of the present study.
In these tumours, E/R content proved to be a "perfect"
marker for hormone-dependence, there being no "overlap"
whatsoever in the ranges of levels encountered in a group
of 12 DMBA-induced tumours and in a group of 12 transplantable
tumours. This difference is more clear-cut than that found
in a previous report from this department (Hawkins et al.,
1978) of 10 DMBA-induced and 12 transplantable tumours. In
that report, a significant difference (p <0.01) was found
between the E/R levels in the two types of tumour but there
was considerable overlap between the groups, with the levels
found in DMBA-induced tumours being much lower than those
observed in the present study. This discrepancy may be
explained, at least in part, by the fact that the host
animals were not exsanguinated prior to removal of the tumour
specimens and high blood content can interfere with E/R
assay techniques (Hawkins et al. 1978). Certainly, in a
previous study (Hawkins et al., 1977), where DMBA-induced
tumours alone were examined, the range of levels of E/R
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found were closer to those found by the present author.
In a further study from this department (Scott et al., 1979)
a significant difference (p <-0.01 ) was found between the two
types of tumours but, again, the ranges were not as distinct
as in the present study.
Pg/R also emerged as an excellent marker for hormone-
dependence. Por this protein, the ranges of levels found
in the two groups were, again, quite distinct with the
exception of a single DMBA-induced tumour in which no Pg/R
was detectable. It might be postulated that this tumour
may have belonged to the hormone-independent minority of
DMBA-induced tumours.
In the case of peroxidase, there was a highly signifi
cant difference (p <0.001) between the levels found in the
two types of tumour, confirming that peroxidase does serve
as a marker for hormone-dependence. However, there was
considerable overlap between the ranges of values found in
the two groups. Under the conditions of this study, therefor
endogenous peroxidase would seem to be inferior to both
E/R and Pg/R as a marker for hormone-dependence. Lyttle
and DeSombre (1979) used a biochemical assay very similar
to that of the present author to measure peroxidase levels
in mouse mammary tumour models for hormone-dependent and
-independent growth. In their study, there was no overlap
between the ranges of peroxidase levels encountered in the
two groups of tumours indicating that, under some circum¬
stances, peroxidase serves as an excellent marker for hormone
dependence.
171
E. Peroxidase As A Marker For Hormone - Dependence
In Human Mammary Cancers.
The finding of a relationship between peroxidase
levels and hormone-dependence in rat mammary tumour models
prompted the evaluation of peroxidase as a marker for hormone-
dependence in a series of human cancers (Results IV).
Peroxidase activity was detectable in 11 of 17 (65%) tumours
examined. This incidence of "peroxidase-positivity" is
similar to those quoted by other investigators: 77% of
39 tumours (Lyttle and DeSombre, 1977), 62% of 52 tumours
(Duffy and Duffy, 1978) and 68% of 130 tumours (Collings
and Savage, 1979).
The incidence of "E/R-positivity" found in the present
series was 65% and, again, this figure is similar to those
generally reported by others (Hawkins et al., 1980). There
was, however, no relationship between tumour peroxidase
content and either E/R status or absolute level of E/R.
In particular, of 6 tumours designated E/R-negative, 4 were
peroxidase-positive. As the predictive value of negative
E/R status is well established, this finding suggests that
peroxidase is unlikely to be a useful marker for hormone-
dependence in human cancers. Duffy and Duffy (1978), in a
series of 52 cancers, did find a relationship between peroxi¬
dase content and E/R status: 78% of E/R-positive tumours
contained peroxidase compared with only 20% of E/R-negative
cases. However, Collings and Savage (1979), in their much
larger series of 130 tumours, were unable to demonstrate
any such relationship. Their finding that 717° of E/R-negative
tumours contained significant peroxidase activity more closely
resembles the present work and must be regarded as discouraging.
Data concerning response to endocrine therapies was
available for only 3 of the 17 cases in the present study
and can only be regarded as anecdotal. However, the finding
of the highest peroxidase level in an E/R-negative, endocrine-
unresponsive tumour, again suggests that peroxidase assays
are unlikely to prove clinically useful.
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F. The Histochemical Assessment Of Peroxidase Activity
In Rat Mammary Tumour Models.
The studies discussed above utilised a biochemical
assay for the measurement of peroxidase activity in tissue
extracts. Some investigations into the properties of
oestrogen-induced peroxidase have used an alternative,
histochemical technique; such studies include work on the
uterus by Brockelmann and Fawcett (1368) and by Anderson
et al., (1975) and also work on rat mammary tumours by
Anderson et al. (1975) and by DeSombre et al. (1975)- In
these studies, stained sections were examined at the electron
microscope level in order to determine the subcellular
distribution of the peroxidase. As a result, DeSombre et al.
(1975) suggested that identification of peroxidase at light
microscope level might be an indication of hormone-dependence
in mammary tumours.
In the present work, this possibility was evaluated
by comparing the peroxidase contents of rat mammary tumours
after assessment by both biochemical and histochemical
methods (Results V). Peroxidase levels determined biochemi¬
cally were significantly higher in the hormone-dependent
than in the hormone-independent tumours. This finding is
in agreement with the results of the previous study (Results III).
It was surprising, however, to find an inverse relationship
between peroxidase activity as assessed histochemically and
hormone-dependence'. Moreover, those tumours designated
histochemically positive for peroxidase had significantly
lower biochemical values than those designated histochemically
negative.
Both the guaiacol and diaminobenzidine reactions are
well established techniques for the demonstration of peroxi¬
dase activity, and this great discrepancy between the results
of the two methods in the rat mammary tumour models is
difficult to explain. It is possible that differences in
the preparation of tissues for the two techniques result in
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differing levels of enzymes such as oxidases and catalases
which may interfere with peroxidase assay systems. Irrespec¬
tive of the cause, however, this paradoxical finding indicates
that extrapolation cannot be made from a correlation between
biochemical estimates of peroxidase and hormone-dependence
to a clinically useful test based on histochemical examina¬
tion of frozen sections.
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G. Conclusions
The Present Status Of Peroxidase As A Marker
Por Hormone-Dependence
The studies presented in this thesis allow the
following conclusions to "be drawn concerning the possible
role of peroxidase as a marker for hormone-dependence:
1. Peroxidase is widely distributed in normal rat tissues,
both classical oestrogen-target tissues such as uterus
and non-target tissues such as spleen.
2. In common with the established "marker-proteins",
3/R and Pg/R, high levels of peroxidase are found in
the uterus. In addition, the finding here and in the
work of others, that uterine peroxidase, in parallel
with Pg/R, is highest in the presence of maximal
"oestrogen-E/R interaction" lends support to the hypo¬
thesis that peroxidase synthesis is induced by an
oestrogen-mediated effect on the genetic material of
the cell nucleus.
3. Peroxidase content in rat mammary tumour models is
significantly related to hormone-dependence. However,
peroxidase is inferior, as a marker, to both E/R and
Pg/R.
4. In contrast, the currently available evidence indicates
that peroxidase does not serve as a marker for hormone-
dependence in human mammary cancers.
5. In rat mammary tumour models, there is no direct
relationship between biochemical and histochemical
estimates of peroxidase activity. This suggests that
the two assay systems reflect different properties and
that staining of frozen sections for peroxidase is
unlikely to prove useful in the prediction of hormone-
dependence.
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In summary, much evidence exists to indicate that
peroxidase-synthesis in oestrogen-target tissues is
stimulated by an oestrogen-mediated effect on the genetic
material of the cell nucleus. Unfortunately, assay of
peroxidase activity would seem to be inferior, in practice,
to assays of cytoplasmic E/R and of Pg/R, for predicting
hormone-dependence. In addition, biochemical and histo-
chemical estimates of peroxidase activity differ markedly.
These observations make it seem unlikely that peroxidase
will prove clinically useful in assessing endocrine-respon¬
siveness in mammary cancers.
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II. A HISTOCHEMICAL APPROACH TO THE IDENTIFICATION OP
OESTROGEH RECEPTORS
In the absence of a currently available, specific
antibody to the E/R protein, two approaches to the identi¬
fication of E/R in tissue sections are available. Indirect
immunohistological methods utilising an antibody raised
against oestradiol have been investigated by many groups,
notably Nenci et al. (1976), Malan & Janss (1978), Mercer et al.
(I978ab & 1979ab), Pertschuk et al. (1978) and Walker et al.
(1980). A second approach involves the use of histochemical
staining techniques. Those groups who have investigated
both immunohistological and histochemical methods (Pertschuk
et al., 1979; Walker et al., 1980) both report that the
latter give superior results. Because of the views expressed
by these investigators, histochemical rather than immuno¬
histological techniques were selected for evaluation in the
present work.
A. Quantitation Of Losses Of E/R Activity During
Histochemical Processing.
In the series of experiments described in "Results ¥1"
an attempt was made to quantitate the possible losses of E/R
activity occurring during various processes which are com¬
ponents of histochemical techniques. It would appear that
even the simple manoeuvre of dividing a portion of tissue
into frozen sections may result in the loss of over 50^ of
measurable E/R activity. The cutting of frozen sections of
thickness 4 Mm (as recommended by Pertschuk et al., 1979),
or even 14 Mm (as recommended by Lee, 1979), inevitably
results in the transection of many cells. It is possible
that this cellular disruption permits a portion of the
soluble cytoplasm, of which E/R is a component, to escape
onto the cryostat knife. A second possible explanation for
the loss of E/R activity observed may be that section-cutting
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results in local heat production at the section surface
with consequent damage to the thermolabile E/R protein.
Following the cutting and mounting of the frozen-
sections, the next step in most histochemical techniques
is some form of fixation to ensure adhesion of the sections
to the glass and to achieve "immobilisation" of proteins
within the section. In view of the possible deleterious
effects of conventional fixatives on E/R activity, many
investigators have dispensed with fixation at this stage
and have relied, simply, on a period of "air-drying"
(Dandliker et al., 1978; Lee, 1978; Pertschuk et al.,
1979)- Lee admits that this failure to effectively
"immobilise" the E/R protein may result in a loss of activity
"Conceivably, an undetermined amount of receptor
protein that is not firmly bound to the sub¬
cellular structures might become dissociated
from the tissue sections. This loss, if any,
is considered inevitable due to limitation of
the methodology."
The experiment described on p.110 was designed in an
attempt to quantitata just such, losses from unfixed frozen
sections into an aqueous medium analogous to the steroid-
containing incubation medium of histochemical techniques.
Under the conditions of this experiment, 66?£ of E/R appeared
to "leach-out" from 14 jum sections, and 753^ from 4 /im
sections, into the aqueous medium. Losses of this magni¬
tude are probably well in excess of those which would occur
in a genuine histochemical technique; in the model system
used the sections were unmounted and were therefore exposed
to the medium on both surfaces, and also the process of
separating sections from medium was somewhat less gentle
than would be achieved under histochemical conditions.
Nevertheless, it would appear that very significant losses
of E/R activity might occur when unfixed frozen sections
are exposed to aqueous processing media.
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Walker et al. (1980) adopted a more conventional
approach to immobilisation of proteins, fixing their frozen
sections by immersion in acetone for 4- min. prior to incu¬
bation with peroxidase-labelled oestradiol. The present
author was concerned that such treatment might denature the
E/R protein, resulting in loss of activity. The experiments
described on p. 112 were undertaken in an attempt to quantitate
these losses. Initially, cytosols prepared from acetone-
fixed, rat uterine fragments were assayed for E/R activity
by routine DCG assay and were found to contain minimal E/R.
It was realised, however, that if acetone-fixation had
successfully immobilised the E/R protein, E/R activity
would not be detectable in the cytosol but would remain
in the homogenisation pellet. Subsequently, therefore,
the homogenisation pellets from acetone-fixed and from
unfixed uterine fragments were assayed for E/R by a "solid-
phase" technique. In the case of unfixed tissue, no E/R
was demonstrable in the pellet preparation, indicating
that, in the unfixed state, all the E/R detectable by the
techniques used is localised in the soluble cytoplasm.
In the case of acetone-fixed tissue, a small amount of E/R
activity was detectable in the pellet preparation. This
finding suggests that acetone-fixation may be a valid step
in histochemical E/R assays; however, both the concentration
(P ) and the dissociation constant (K^) were markedly
impaired in comparison with those of E/R in the cytosol of
unfixed tissue. The loss of E/R activity attributable to
acetone-fixation appeared to be about 50%, similar to the
magnitude of loss caused by "leaching - out" of E/R in the
case of unfixed tissues.
Lee (1978) similarly reported that exposure of
tissues to acetone (at -20°C) results in almost complete
abolition of cellular, oestrogen binding capacity. Lee
also investigated 3.7% buffered formaldehyde and 1% glutar-
aldehyde as possible fixatives, but felt that these sub¬
stances also resulted in loss of E/R activity and that
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air-drying was the most practical approach to E/R
immobilisation. Dandliker et al. (1978) investigated
the effects of 4% formalin (1% formaldehyde) on E/R activity
in a quantitative manner. They estimated that E/R activity
in formalin-fixed tissues was only 20 - 40% of that detect¬
able in equivalent, untreated tissues. These investigators
also concluded that air-drying gave the best results in
practice.
lee (1978) did not expose frozen sections to fixative
agents at any stage of his histochemical technique;
Pertschuk (1979), however, employed "post-fixation" in
ethanol/acetone after the incubation of sections with
fluorescein-conjugated oestradiol. The present author was
concerned that exposure to such a fixative at this stage
might result in breakage of the bonds between E/R and the
labelled oestradiol. The experiment described on p.116
demonstrated that such a breakage does, in fact, occur when
tritiated oestradiol is used as a tracer. It might be
argued that this breakage of the oestradiol-E/R bond is
unimportant when an albumin-containing tracer, as in
Pertschuk's technique, is used because the fixation would
serve to immobilise the protein conjugate at the site of
E/R interaction. However, such a mechanism would also
result in the immobilisation of any non-specifically
deposited conjugate and would, presumably, prevent it from
being removed by subsequent washing procedures.
In summary, this preliminary series of experiments
has indicated that significant losses of E/R activity
might be expected to occur during the actual cutting of
frozen sections, during exposure of unfixed tissues to
aqueous media and during exposure to fixatives, either
before or after the incubation of sections with oestradiol
linked to a visible tracer. These possible losses of activity
during histochemical methods for E/R determination are
summarised in Table 16 .
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Table 15.
Summary of the sites and magnitude of losses of E/R
activity which may occur when tissues are exposed
to histochemical processing.
PROCESS AUTHOR % LOSS
Section cutting Present Work 50
Exposure of unfixed
tissue to aqueous
media.
If 66-75
Fixation in acetone If 50
If Lee (1978) "almost total"
Fixation in glut-
araldehyde.
If If
Fixation in form¬
aldehyde .
If if
if Dandliker et al
(1 978)
60-80
"post-fixation"
in etano1/acetone
Present work "almost total
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B. Possible Approaches To Minimising: losses Of B/R Activity
In view of the finding that losses of E/R activity
of up to 50$ might accrue from exposure to conventional
fixatives or from exposure of unfixed tissues to aqueous
media, two alternative approaches to protein-immobilisation
were investigated. Both ammonium sulphate and protamine
sulphate are reported to precipitate S/R into a solid-phase
without loss of activity (Dandliker st al., 1978; Steggles
and King, 1970). Preliminary studies employing radioactive
oestrogen as tracer were undertaken to establish whether or
not either of these compounds might prove useful for the
immobilisation of E/R in a histochemical situation.
In the experiment described on p.119 ammonium
sulphate was found to be very effective in preventing the
"leaching-out" of E/R from unfixed frozen sections. In
this study, 82$ of E/R activity leached out into an aqueous
medium in the absence of ammonium sulphate, but this loss
was reduced to 10$ by the presence of 50$ saturated ammonium
sulphate. Unfortunately, when such treatment was applied
to the assay of E/R in glass-mounted frozen-sections (p. 131 ),
a situation more closely resembling an actual histochemical
technique, results proved less satisfactory. The addition
of ammonium sulphate to processing media in this system
resulted in very high "non-specific" binding which was not
blocked by coincubation with unlabelled steroid.
The preliminary work with protamine sulphate (p.123 )
served to confirm the finding of Lippman and Huff (1977)
that E/R can be precipitated by protamine without loss of
activity. In the present study the concentration (EQ) of
E/R was unimpaired by precipitation but, unlike Lippman
and Huff, the present author found the strength of binding
(as reflected by K^) to be diminished. When protamine-
treatment was used in the glass-mounted system (p. 133 )
some E/R activity was demonstrable; high non-specific
binding such as had occurred with ammonium sulphate did not
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arise. However, the differential labelling between sections
incubated with £ Hjj alone and those coincubated with
°E2 achieved after protamine-treatment was inferior to
that achieved after acetone-treatment using the sam9 assay
*2
system. Using protamine, less than 50ft of total [/H^ E2
uptake could be attributed to "specific" labelling, compared
with up to 86/° using acetone-treatment.
In summary, most investigators in the field of E/R
histochemistry employ one of two approaches to the problem
of E/R-immobilisation without inactivation. Either a
conventional fixative, such as acetone, is used or fixation
is avoided and sections are simply air-dried. The author
has investigated these two approaches and also two novel
approaches (ammonium sulphate and protamine sulphate
precipitation) in a model for a histochemical technique using
the well-established tracer, [jEj oestradiol. Under these
conditions, acetone-fixation produced more clear-cut and
reproducible differential labelling than the other approaches.
However, acetone fixation results in the loss of much
activity before the receptor can finally be visualised and,
hence, assays incorporating 3uch a step cannot exhibit
optimal sensitivity.
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C. Selection Of Oestradiol Conjugates.
A range of conjugates of oestradiol with a visible
tracer have been advocated by investigators in the field
of E/R histochemistry. The conjugates described can be
divided into two main groups: those where oestradiol is
linked to the tracer via the Cg position and those linked
via the position. Important examples of these two
groups of conjugates are illustrated in Figures 34 and 35 .
The nature of the bond between oestradiol and its
receptor is not yet fully elucidated, but Ellis and Ringold
(1971) indicate that the hydroxyl groups at the and
positions on the oestradiol molecule are involved in binding.
If, in fact, this is the case then conjugation at the Cg
position, which leaves the hydroxyl group at intact,
would be expected to produce a conjugate with superior
binding properties to one utilising the position. A
further theoretical point in favour of the Cg position as
the site of conjugation is that linkage to albumin at this
position retains the antigenic specificity of the oestradiol
molecule (Lindner et al., 1972) and might, therefore, be
expected to retain functional specificity also. Figure 36
illustrates work from this department confirming the anti¬
genic similarity between oestradiol 17jB and Cg-linked
derivatives. Lee (1978) quoted this antigenic similarity
as his rationale for the selection of a "Cg" conjugate.
Dandliker et al. (1978) synthesised a range of
oestradiol-fluorescein conjugates and measured their binding
affinities to E/R in comparison with oestradiol 17^. Their
original conjugate, known as 6-FE (compound 1, Fig. 34 )
was found to have a relative binding affinity of less than
0.01. They experimented with the insertion of a "5 carbon
spacer bridge" in the 6-FE molecule (compound 2, Fig. 34 )
but still found the relative binding affinity to be less
than 0.01. Despite the theoretical objections, Dandliker
and co-workers then synthesised the compound 17-FE
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Figure 34- •
Oestradiol conjugates involving conjugation at the Cg
position which have been described as useful for the
histochemical localisation of E/R. The parent molecule,
oestradiol-17B, is also shown.
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oestradiol \1[3
fluorescein
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©
carboxy- methyl •
oxime
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Dandliker etal
® > x 5
hemisuccinate
bridge
Pertschuk et.al.
Figure 35 ■
□estradiol conjugates involving conjugation at the C^-,
position which have been described as useful for the
histochemical localisation of E/R. The parent molecule,
oestradio 1- 17B, is also shown.
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competitors
o ° oestradiol 17/3
6-keto-oestradiol 17/3
£—a 6-keto-oestradiol BSA
1 10 100
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Figure 36 .
Relative affinities of Oestradiol 17B, 6-keto-oestradiol 17B
and 6-keto-oestradiol 6-CMO-BSA for binding to an antibody
generated against 6-keto-17B oestradio 1-6-CMO-BSA.
Varying masses of each compound were allowed to compete
3
with a fixed mass of ( HIE^ ( 0.037 pmoles.)during binding,
overnight, to rabbit antiserum at a final dilution of
1/98,400.
(This assay was kindly performed by Miss K Sangster.)
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(compound 5, Fig. 35) and obtained a relative affinity of
0.03 which is, at least marginally, more acceptable. Very
recently, Barrows et al. (1980) have published their
experiences with a similar oestradiol-fluorescein conjugate
utilising the position for conjugation. They reported
a relative binding affinity approaching 0.1.
The site on the oestradiol molecule utilised for
conjugation is only one point of difference between the
various conjugates which have been used for E/R histo¬
chemistry. A second variable is that some investigators
have employed simple oestradiol-fluorescein conjugates,
such as the 6-FS and 17-FS of Danaliker et al. (1978),
whereas others have linked oestradiol to tracer via an
intervening molecule of BSA. The proposed advantages of
conjugation via BSA are twofold. Firstly, because more than
one molecule of tracer may be incorporated into each conju¬
gate molecule, the si/stem results in an "amplification"
of E/R-labelling (assuming that only one of the several
oestradiol molecules in the conjugate is available for
binding to E/R). Secondly, the BSA serves as a protein
"carrier" and improves the solubility of the steroid conjugate.
Lee (1978) regards this improved solubility as essential in
view of the very high steroid concentrations required for
his histochemical method. Of those workers who have used
BSA-containing conjugates, Lee (1978) and Walker et al. (1930)
have employed conjugation at the Cg position and have used
fluorescein or peroxidase respectively as tracers (compounds
3 and 4, Pig.34 )• Pertschuk et al. (1979), on the other
hand, have employed fluorescein as tracer conjugated via
the Opposition (compound 6, Pig. 35) •
In the present stud3^, the effects of conjugation
at the Opposition on affinity of binding to E/R have been
investigated (p 139 ). The results indicate that any
"interference" with the Cg position markedly impairs affinity
of binding to E/R, in contrast to the minimal effect of such
"interference" on binding to anti-oestradiol antibody (Pig. 36).
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The simple addition of a keto group at Og reduced the
relative binding affinity to 0.13 (similar to the value of
0.22 quoted by Dandliker et ah, 1978 for this compound).
Conjugation to BSA further reduced the relative binding
affinity to 0.09 and the final oestradiol-BSA-peroxidase
conjugate, as used bjr Walker et al. (1980), had a relative
affinity of only 0.02.
In contrast to the poor binding affinities of these
"G^n conjugates, a compound comprising oestradiol, BSA and
fluorescein conjugated via the position prepared by the
author had a relative affinity of 0.05 and a similar conjugate
donated by Dr. 1. Pertsch.uk had a value of 0.8. This last
value is undoubtedly impressive but the point made by
Dandliker et al. (1978) regarding the activities of such
compounds must be heeded in its interpretation:
"In establishing the activities of fluorescent
hormone derivatives, a crucial point must be kept
in mind. Assessment of activity by inhibition, of
I3d oestradiol binding alone is not sufficient
clearly to establish activity of the fluorescent
conjugate, especially if the relative affinity is
low (<2yo). In this situation a small amount of an
active contaminant, or a small amount of degradation
resulting in liberation of free, unlabelled hormone
could lead to an inflated estimate of the relative
affinity."
The possibility that such a situation pertained with regard
to the specimen of Dr. Pertschuk's conjugate analysed cannot
be excluded.
•
In summary, labelled conjugates of oestradiol which
have been reported to be useful for E/R histochemistry have
involved conjugation at either the Cg or C,( ^ position, and
have involved either direct linkage of oestradiol to the
tracer or linkage via a molecule of BSA. Despite the
1»9
theoretical advantages of conjugation at Cg, the binding
affinities of such compounds are, in practice, inferior
to those of^"conjugates. The incorporation of B3A into
the conjugate has theoretical advantages in terms of ampli¬
fication of E/R labelling and improved conjugate-solubility.
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D. Concentration of.Oestradiol Conjugates
In addition to variations in the nature of the
oestradiol conjugate selected, as discussed above, the
various investigators in the field of E/R histochemistry
have also differed with regard to the concentration of
conjugate employed. For E/R assay systems in general, it
is felt that a concentration of labelled oestradiol which
is adequate to saturate the receptor, but which is not vastly
in excess of the saturating concentration, should be used.
Concentrations of 1 to 5 nM (McGuire et al., 1977; King et al.,
1979) have been suggested as suitable for biochemical
techniques utilising a single saturating dose of [^hQ
oestradiol. If concentrations vastly in excess of the
saturating dose are employed, binding to proteins of low
affinity is increased, i.e. there is high "non-specific
binding". It should be noted that at sufficiently high
oestrogen concentrations, binding to serum albumin
(Kj = 10~4 - 10~5 Molar) and other low affinity binding
proteins will be seen. In addition, this binding can be
"blocked" by still larger excesses of unlabelled compound.
Such binding and displacement are not, of course, related
to E/R activity but might be a source of misinterpretation
of histochemical appearances.
The concentrations of fluorescent oestradiol (17-FE)
of 2 nM and 30 nM used by Dandliker et al. (1978), and by
Barrows et al. (1978), are of the same order as the range
quoted for biochemical assays and would not, therefore, be
expected to give rise to excessive "non-specific binding".
Those investigators who have employed albumin-containing
conjugates have, however, used much higher concentrations.
Pertschuk et al. (1979) recommended a concentration of
1400 nM with respect to oestradiol, equivalent to a conjugate
concentration of around 370 nM. Lee (1978 & 1980) used an
even higher concentration of 1,000,000 nM with respect to
oestradiol, equivalent to a conjugate concentration of
around 40,000 nM. Walker et al. (1980), who used a conjugate
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similar in structure to that of Lee, did not quote a working
concentration but stated that it must be determined empiri¬
cally by testing various dilutions of the synthesised
material.
The conjugate concentrations recommended by the
latter groups appear excessive. However, it must be borne
in mind that the oestradiol-BSA-fluorescein conjugate used
by Pertschuk may have a binding affinity for 3/R of only
1/20 of that of oestradiol (estimate on conjugate synthesised
by present author). On this basis it might be considered
justifiable to use a conjugate concentration 20X as great
as that recommended for oestradiol, but Pertschuk's 370 nil
is still in excess of this. Similarly, the binding affinity
of an oestradiol-BSA-peroxidase conjugate of similar structure
to those used by Lee and Walker may be only 1/50 of that of
oestradiol 17J3 (present author's estimate). 3ven allowing
for this, the 40,000 nil conjugate concentration of Lee would
seem to be excessive, and might be expected to result in
unacceptably high non-specific binding.
A further point to be borne in mind in justification
of the high conjugate concentrations advocated by some
investigators is that 3/R in a solid phase has a lower
effective binding affinity for oestrogens than that of the
cytosol protein in a liquid phase. This author's experiments
wich acetone- and protamine-precipitated pellets reflected
this apparent alteration in affinity in elevated values of
Kj. Such an alteration in the binding properties of B/R
means that a higher steroid concentration is needed to achieve
saturation. It also means, however, that the binding pro¬
perties of B/R are approaching those of non-specific binding
proteins.
In summary, the range of concentrations of labelled
oestradiol conjugates advocated by various investigators
is very wide. Some of the recommended concentrations seem
excessive in comparison with those generally recommended for
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S/R saturation. Such increased concentrations can, at
least in part, "be justified on the basis of the relatively-
low binding affinities of the conjugates and of the appar¬
ently impaired binding properties of the E/R protein under
histochemical (solid phase) conditions.
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B. Evaluation Of Histochemical Techniques In Practice.
The essential "basis of any E/R assay system is the
demonstration of tissue uptake of labelled oestradiol which
can be blocked by saturation of the receptors with an excess
of an appropriate, unlabelled competitor. Failure to
demonstrate such blocking in any assay system must raise
serious doubts as to whether or not tissue-labelling can be
genuinely attributed to E/R activity. With this principle
in mind, it may be considered that the following criteria
should be noted when examining the results claimed for
E/R-histochemistry techniques: firstly, the demonstration
of discrete, localised tissue-labelling; secondly, the
blocking of such labelling with appropriate competitors
and thirdly, correlation with the results of biochemical
E/R assays. The results of various investigators, including
the author's experiences with two well-documented histo¬
chemical techniques, will now be discussed with regard to
these criteria.
a) Studies With Simple Fluorescein-Oestradiol Derivatives
Dandliker et al. (1973) incubated unfixed sections of
rabbit uterus with their compound 17-FB and were able to
demonstrate discrete fluorescein-labelling, largely localised
to the endometrium, at steroid concentrations of 2 - 5 nil.
Unfortunately, they were unable to demonstrate blocking of
such labelling by co-incubation with unlabelled oestradiol
or diethylstilboestrol at a concentration of 1.2 juM
(approximately 200x excess). In addition, they found that
incubation with their compound 6-FB (shown to have a very
low binding affinity for E/R), with oestrone labelled with
fluorescein at
^ and with progesterone labelled at CL,
gave rise to identical staining patterns. As regards
correlation with the results of cytosol E/R assays, these
authors examined two human mammary tumours, both designated
E/R positive by SDG assay. They found that one became .
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labelled with 17-EE and that the other did not. I must
concur with the conclusion drawn by Dandliker et al. from
their results:
"Because many factors may be involved in the
staining observed, we cannot at present attribute
the staining to any one, such as the localised
presence of oestradiol receptors."
More recently, Barrows et al. (1980) reported on studies
with a compound designated which differed from the
17-EE of the previous group in that fluorescein was linked
to oestradiol at via a succinamide-ethyl-amine bridge
rather than a carboxy-methyl-oxime bridge. In their
studies, Barrows et al. investigated the "temperature-
dependent nuclear transfer" of FE^ as a marker for E/R
action rather than the simple cytoplasmic uptake of the
labelled steroid. They reported that cytoplasmic labelling
occurred in some oestrogen-independent tissues such as liver
or gut mucosa but that nuclear-transfer occurred only in
target tissues such as endometrium and prostatic and
mammary cancers. These investigators reported a measure of
success in blocking this nuclear-labelling with appropriate
competitors: partial blocking was achieved by pre-incubation
—
with oestradiol at a concentration of 10 M (approximately
300x excess), but for complete blocking a mixture of saturated
solutions of diethylstilboe3trol, equinilone, oestradiol
and oestrone was required! Barrows and co-workers were able
to compare the results of their technique with those of
cytosol E/R assay in 17 cases of human mammary cancer and
report a significant (though far from perfect) correlation.
b) Studies With Albumin-Containinv Oestradiol Conjugates
Lee (1978 and 1980) incubated unfixed frozen sections
with a Cg-linked conjugate of oestradiol, BSA and fluorescein.
He reported that E/R-negative tissues (appendix, tonsils and
carcinomas of stomach and colon) failed to take up the
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fluorescent stain but that some cells of human mammary
cancers exhibited brilliant, green fluorescence. In common
with other investigators, lee admitted to experiencing
difficulty in successfully blocking fluorescent labelling.
He maintained that oestradiol is insufficiently soluble
in aqueous media to reach concentrations high enough to
compete with the 1 mM steroid concentration in his conjugate
solution. He was able to achieve blocking by using a
conjugate of oestradiol with a BSA "carrier" to improve
solubility. Lee admitted, however, that various modifications
had to be made to his routine technique to achieve complete
blocking: either his normal conjugate concentration had to
be reduced by a factor of 10, or a modified conjugate with a
low steroid : protein ratio had to be used. In addition,
blocking studies were carried out at 4°C rather than the
routine room-temperature. It is difficult to accept, in
view of these major differences between experimental and
control sections, that blocking has been achieved by Lee.
In his later report, Lee (1980) claimed an incidence of
"E/R-positivity" of 747^ as assigned by his technique. This
is of the same order as the E/R-positive incidence usually
quoted using conventional techniques (Hawkins et al., 1980).
With regard to the correlation between histochemical and
biochemical estimates of E/R status, Lee (1979) reported
on 40 tumours assayed in both ways and found no correlation.
In his 1980 report he also stated that there was no direct
correlation.
In the technique of Pertschuk et al. (1979),
unfixed, frozen sections were incubated with a C^-linked
conjugate of oestradiol, BSA and fluorescein, then
"post-fixed" in ethanol/acetone. They reported the finding
of bright, discrete cytoplasmic and/or nuclear fluorescence
in mammary cancer specimens and MCE-7 cells after incubation
with conjugate. This fluorescence was significantly or
completely blocked by co-incubation with 100 - 500x excess
of oestradiol, diethylstilboestrol or CI-628. In addition,
sections incubated with a "control" conjugate of BSA and
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fluorescein exhibited only minimal fluorescence. In two
series of 101 and 226 cases respectively (Pertschuk et al.,
1979 and 1979°), there was a correlation of 82j£ and of 92/£
with the results of conventional assays. In the hands of
its originators, therefore, this technique would seem to
fulfil all the requirements of a satisfactory E/R assay
system: discrete tissue-labelling, blocking by appropriate
competitors and good correlation with the results of
conventional assays.
The attempts of the present author to reproduce
these results are presented in "Results XI". Oestrogen-
target cells such as those of rat endometrium did exhibit
a bright fluorescence after incubation with conjugate, but
this labelling could not be blocked bj' even very high
concentrations of competitors. In addition, E/R-negative
tissues such as rat duodenum exhibited a very similar
staining pattern to that seen in uterus. In these studies,
therefore, it would appear that all the tissue-labelling
observed could be attributed to non-specific uptake. In
view of the comments made above about the effects of post-
fixation with ethanol/acetone, a high level of non-specific
staining might be expected, on theoretical grounds, using
a technique of this type.
Walker et al. (1980) used a Or-linked conjugate ofo
©estradiol, B3A and peroxidase on acetone-fixed frozen
sections. By this method they were able to demonstrate
strongly-staining cells in endometrium and myometrium of
rat uterus and also to demonstrate cytoplasmic and/or
nuclear staining in some cells of human breast cancers.
Sections of rat lung, regarded by these authors as an
E/R~negative tissue, failed to exhibit staining. They
reported that positive staining could, in all cases, be
completely blocked by co-incubation with tamoxifen. The
concentration of tamoxifen required was not stated in their
publication but a personal communication from Br. Walker
indicated that a saturated solution was used. Results of
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the histochemical method were compared with those of
DOC assay in 35 cancers and a reasonable correlation was
found, like the technique of Pertschuk, therefore, this
method would appear, at least as performed by its originators,
to fulfil all the criteria for a valid E/R assay system.
The first problem encountered by the present author
during evaluation of this approach was the presence of
endogenous peroxidase activity in the tissues under stud;/.
In most immunohistological techniques utilising peroxidase
as a tracer, it is standard practice to pre-treat tissue
sections in a manner designed to destro;/ endogenous peroxidase
activity prior to incubation with peroxidase-labelled anti-
sera. One such method of treatment is to immerse sections
in a solution of 3% hydrogen peroxide in methanol. Exposure
to such a medium would almost certainly destroy the
functional integrity of E/R, which is less robust than the
antigenic determinants of most proteins (Walker, personal
communication) and it is, therefore, considered impractical
to remove endogenous peroxidase from tissues prior to
E/R-histochemistry. In the present study a pronounced
endogenous peroxidase reaction was observed in human
endometrial cells and also in the E/R-negative tissue, rat
duodenum. The presence of this staining made it impossible
to determine whether or not any additional peroxidase-
staining, attributable to specific binding of conjugate,
had occurred and would seem to preclude the use of these
readily available tissues, of established receptor status,
in the validation of this technique.
The experiences of this authour with the method of
Walker et al. in 25 tissues without detectable endogenous
peroxidase staining are presented in Results (147).
In agreement with the report of Walker et al. (1980), cellular
uptake of conjugate was demonstrable in many biochemically
E/R-positive tissues. In this author's hands, however,
such uptake was also demonstrable in many tissues which were
biochemically E/R-negative. Walker et al. claimed that
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"blocking of conjugate-uptake was achieved in all cases
with tamoxifen. The present author however, in common with
many others in the field of E/R-hist©chemistry, found
blocking to be very difficult to achieve and to be only
partial in most instances.
Using the demonstration of cellular uptake of
conjugate which could be blocked by coircubation with
competitor as the criterion for designating a tissue E/R-
positive, and taking absent uptake as the criterion for
designating a tissue E/R-negative, this author found
agreement with DCC assay in only 6 of 25 tissues studied.
In summary therefore, the results of Dandliker et al.
(1979), with their compound 17-EE, fail to fulfill the
criteria for B/R determination in that blocking of cellular-
labelling could not be demonstrated. The results of
Barrows et al. (1980) and of lee (1978 and 1980) may be
regarded as more encouraging though their demonstrations
of blocking cannot be regarded as entirely satisfactory in
that Barrows et al. found it necessary to employ a remarkable
"cocktail" of oestrogens and Lee had to modify his assay
conditions for the "control" sections. In the hands of their
originators, the methods of Pertschuk et al. (1979) and of
Walker et al. (i960) would appear promising, but it remains
for their successes to be duplicated in other centres. The
present author has been unable to reproduce the specificity
of staining, the effectiveness of blocking and the excellence
of correlation with the results of biochemical assay reported
by these groups.
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F. Summary and Conclusions
The studies presented in this thesis allow the
following conclusions concerning histcchemical techniques
for the identification of E/R to "be drawn:
1. Losses of E/R activity would seen to occur at every
stage of histochemical processing. Reduction in E/R activity
has "been demonstrated during the actual cutting of frozen
sections, during exposure of tissue to fixatives or, in the
case of unfixed tissues, during exposure to aqueous media.
Overall, it appears that perhaps only 25/ of the E/R activity
originally present in a tissue remains "viable" for
histochemical labelling.
2. Prom the results of experiments into various methods
of S/R immobilisation using the well-established tracer,
tritiated oestradiol, it would appear that acetone-fixation
gives superior results to air drying, to ethanol/acetone
post-fixation and also to the two novel approaches investigated,
ammonium sulphate and protamine sulphate precipitation.
5. Various conjugates of oestradiol with tracer
molecules suitable for histochemical localisation are able
to bind to E/R, as judged by competition studies against
tritiated oestradiol. Among the conjugates tested however,
the affinity of binding to S/R is only l/20 to 1/50 of that
exhibited by oestradiol 17jB.
4. Of the conjugates in current use, those conjugated
via the 0^ position on the oestradiol molecule exhibit
superior binding to S/R compared with those conjugated via
rt
^6'
5. It seems necessary to use very high concentrations
of competitors to achieve even partial blocking of conjugate-
uptake. 'This raises the concern that such concentrations
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might serve to saturate even non-specific oestrogen binding
sites and that inhibition of conjugate-uptake by such con¬
centrations may not be truly indicative of bona fide
S/R activity.
6. In techniques employing peroxidase as tracer, the
presence of abundant endogenous peroxidase in many classical
3/R-positive and -negative tissues effectively precludes
the use of such tissues for validation of the techniques.
In summary, there is wide agreement that a reliable
and reproducible technique for the identification of E/R
in tissue sections would represent a significant advance
over current cytosol assays. Excellent correlation with
the results of biochemical assays have been reported by at
least two groups (Pertschuk et al., 1979; walker et al., 1980).
However, the losses of S/R activity inherent in histochemical
processing, the poor binding affinities of the oestradiol
conjugates used, the inconsistencies between concentrations
of conjugates and competitors required and the accepted
binding characteristics of E/R and the lack of reports cf
success with these methods from other centres must raise
serious doubts that E/R is truly being demonstrated.
.201
111. FINAL REMARKS
The Prediction Of Response To Endocrine Therapy
In Mammary Cancer
Thus far, neither a curative therapy for advanced
breast cancer nor an adjuvant therapy of proven worth for
primary disease, is available. Endocrine manipulation
remains, therefore, a major treatment-option for the
palliation of advanced disease and for investigations into
the value of adjuvant therapy. The justification for the
use of endocrine therapies in such situations is facilitated
by the availability of predictive indicators of response.
At the present time, S/R status, as assigned by biochemical,
cytosol assay, remains the best available predictive
indicator. Patients can, with considerable confidence, be
excluded from treatment by hormonal means, on the basis of
negative E/R status, but the clinical value of positive
S/R status is much less. An additional test to identify
that subgroup of E/R-positive tumours which are genuinely
hormone-dependent is still needed. The test evaluated .in
this thesis, peroxidase assay, has failed to fulfill Its
theoretical promise; evidence is accumulating, however, that
progestogen receptor (Pg/R) may be a useful additional
marker and that patients whose cancers possess both E/R
and Pg/R should not be denied hormonal therapy.
In overcoming the limitations of current E/R assay
methodology, histological techniques may ultimately prove
to be of benefit. The techniques discussed in this thesis
depend on the integrity of S/R-oestrogen binding; a property
which seems "fragile" and unsuited to study under standard
histochemical conditions. It may be, however, that the
antigenic determinant of the E/R molecule is more "robust"
and, should a specific antibody to E/R become generally
available, then the detection of S/R in tissue sections may
become a more realistic proposition.
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ABBRE"VTATI PITS
Standard chemical formulae have been used as
required in the text as have established abbreviations
such as g (gram), M (Molar), etc. The following standard
prefixes have been used in association with such units:
m : milli (10-;>)
u : micro (10-tl)
n : nano (10~^)
p : pico (10"12)
f : femto (10"1^)
Other abbreviations have been defined on the first
occasion on which they appear in the text. Per completeness
and ease of reference, an alphabetical list of abbreviations
used is presented here:
A/R : Androgen receptor
BSA : Bovine serum albumin
cpm : Counts per minute (as a measure of
radioactivity)
DAB : Diaminobenzidine tetrahydrochloride
(a histochemical stain for peroxidase)
DCC : Dextran coated charcoal (used in
E/R assays)
DEI : Disease-free interval
Di-jBA 7,12 dimethyl bens(a)anthracene (used
for the induction of rat mammary
tumours)
220
Standard histological mounting medium
Oestradiol 17jB
"TJnlabelled" Oestradiol 17J3 as used
in competition "binding assays
£2,4,6,7 - Oestradiol 17P
(Tritium-labelled for S/R assay)
Enzyme Commission
Oestrogen Receptor
1-fluoro-2,4,-dinitrobenzene
Fluorescein isothiocyanate
Horseradish peroxidase
Dissociation constant
Michaelis constant
Molecular weight
Receptor site concentration, usually
in fmoles/mg wet weight
Fhosphate buffered saline (0.3 M,
pH 7.6) standard buffer for histo- h
chemistry
Progestogen
"Uhlabellea" progestogen (Organon 2058)
as used in competition binding assays
Tritium-labelled Progestogen
(Organon 2058) for Pg/R assay
Progestogen receptor
221
Revolutions per minute
Svedberg unit, a measure of sedi¬
mentation rate
Sucrose Density G-radient (a separation
technique used in S/R assays
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Many workers have shown that human
breast cancers which contain oestrogen
receptors (RE) are more likely to respond
to hormonal therapy than those which do
not (McGuire et al., 1978). RE status, as
determined by conventional techniques is
a relatively poor indicator of responsive¬
ness to hormonal therapies; only 35-63%
of patients classified as RE+ respond to
endocrine ablation (Roberts et al., 1978;
McGuire et al., 1978). Standard RE assay
techniques require up to 300 mg of tumour,
an amount which is often unavailable in
cases presenting early with small primary
tumours, or where metastatic deposits are
inaccessible to open biopsy (e.g. in bone or
liver).
These limitations reduce the clinical
usefulness of RE assays and have led to a
search for alternative indicators of hor¬
mone responsiveness which might dis¬
criminate better and be detected in smaller
tumour samples. Progestogen receptor
(RP) (McGuire et al., 1978) and endogenous
peroxidase (Lyttle & De Sombre, 1977;
Duffy & Duffy, 1977; De Sombre et al.,
1975) are two proteins which have been
suggested as potential indicators of hor¬
mone responsiveness.
The present study was set up to assess
the value of endogenous peroxidase as an
indicator of hormone dependence by
measuring peroxidase levels in rat mam¬
mary tumours which serve as models of
hormone-dependent, and -independent
growth.
DMBA-induced rat mammary tumours
are considered to serve as models of ovary-
depenclent growth. Previous work in our
department has shown that over 80% of
such tumours regress after oophorectomy
(Hawkins et al., 1978; Scott et al., 1979).
Twenty-four such tumours were examined
in this study. Two transplantable lines
(TG3 and TG5) of rat mammary tumour
which exhibit ovary-independent growth
(Hawkins et al., 1978) have been generated
in our department and 20 tumours of these
lines were also examined.
Each of the 44 tumours was dissected
free from the host animal, after ex-
sanguination. The tumour was then homo¬
genized in an ice-cooled tube, at a con¬
centration of 300 mg/ml in cold 10mM
Tris buffer (pH 8-0) with 10% glycerol
(v/v) using a Silverson homogenizer. The
homogenates were centrifuged for 45 min
at 39,000 g to yield a clear cytosol. A
random sample of 12 cytosols from each
group of tumours was then processed by
mixing each with 100 ^1 of monothiogly-
cerol and assaying for RE and RP by
saturation analysis techniques as described
elsewhere (Hawkins et al., 1977, and in
preparation). The cytosols from the other
tumours were discarded.
Each centrifugation pellet was then
homogenized at 300 mg/ml in 10mM Tris
buffer (pH 7-4) containing 0-5m calcium
chloride to solubilize any peroxidase pre¬
sent. The homogenate was centrifuged for
45 min at 39,000 g to yield a clear cytosol
containing the solubilized peroxidase.
This extraction procedure is based on that
of De Sombre & Lyttle (1978).
The cytosol was then assayed for per-
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oxidase by a method based on that of
Himmelhoch et al. (1969). The reaction
mixture in the cuvette comprised 13mM
guaiacol, 0-4mM hydrogen peroxide and
10mM Tris buffer (pH 7-4) containing
O-SmM calcium chloride, in a final volume
of 3 ml. The reaction was started by
addition of cytosol, a volume between
0-1 and 0-5 ml being required to give a
suitable deflection of the spectrophoto¬
meter needle. The rate of reaction was
measured by the change in absorbance at
470 nm between 1 and 3 min after starting
the reaction.
Receptor concentrations were expressed
in fmol/mg of wet tumour and peroxidase
content in u/g wet tumour. One peroxidase
unit was defined as the amount of enzyme
required to produce an increase of one
absorbance unit per minute under the
assay conditions used.
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Fig. I.—Endogenous peroxidase content in
rat mammary tumours which serve as
models for hormone-dependent and inde¬
pendent growth. Each symbol represents
one tumour.
The Wilcoxon rank-sum test was used
to evaluate the differences between "hor¬
mone dependent" and "hormone-inde¬
pendent" tumours for concentrations of
each "indicator-protein".
Fig. 1 shows the endogenous peroxidase
content of each of the 24 DMBA-induced
tumours and each of the 20 transplantable
tumours. Peroxidase was detectable in all
but 2 of the DMBA-induced tumours, but
was undetectable in 6 of the transplant¬
able tumours. Analysis of the levels in the
two groups revealed a highly significant
difference (P < 0-001). Nevertheless there
is a considerable overlap in peroxidase
levels between the "hormone-dependent"
and "independent" tumour models.
Figs. 2 and 3 show the levels of RE and
RP in a random sample of 12 tumours
from each group. Significant differences
were again found between "hormone-
dependent" and "independent" tumours.
In the case of RE there was no overlap
between the groups. RP was undetectable
in one DMBA-induced tumour, but other-
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Fig. 2.—Oestrogen receptor content in rat
mammary tumours which serve as models
for hormone-dependent and independent
growth. Each symbol represents one tumour.
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Fig. 3.—Progestogen receptor content in rat
mammary tumours which serve as models
for hormone-dependent and independent
growth. Each symbol represents one
tumour.
hormone dependence. However, the over
lap in peroxidase levels between th(
largely hormone-dependent, DMBA-in
duced group and the hormone-independenl
transplantable group was considerable
It seems unlikely, therefore, that endo
genous peroxidase will prove to be a more
reliable discriminator than RE.
Our findings are somewhat at variance
with those of Lyttle and his co-worker.1
(1979) in their studies of peroxidase levels
in mouse mammary-tumour models. They
found no overlap between hormone
dependent and independent groups.
Peroxidase can be readily identified by
a simple histochemical technique (D(
Sombre et al., 1975) and could, therefore
be detected in much smaller biopsy speci
mens than are needed for standard RI*
assays. Peroxidase estimations in breas
tumours might, therefore, prove clinically
useful in overcoming one of the limitations
of standard receptor assays—namely, tin
amount of tumour needed. However, th<
findings of this study suggest that per
oxidase is unlikely to provide a mors
accurate prediction of hormone-respon
siveness than RE.
wise the range of levels in the two groups
was quite distinct.
The results obtained in this study indi¬
cate that RE and RP assays clearly dis¬
criminate between hormone dependence
and independence in these rat mammary
tumours. It is known that not all DMBA-
induced tumours are hormone-dependent
and it might be postulated that the one
such tumour in which no RP could be
detected might have belonged to the
hormone-independent minority of DMBA-
induced tumours. This study revealed no
overlap in RE levels between the two
groups but it should be noted that in
earlier generations of the TG3 and TG5
lines higher RE concentrations were found,
and the distinction between the groups was
less clear-cut (Hawkins et al., 1978; Scott
et al., 1979).
Our results support the postulated rela¬
tionship between peroxidase content and
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